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Nucleotide pyrophosphatase/phosphodiesterase (NPP) 7, also known as alkaline 
sphingomyelinase (Alk-SMase) is a membrane-anchored ectoenzyme initially discovered 
in the rat intestinal tract in 1969. It is the most recently identified NPP isoform. The 
family currently consists of seven members, NPP1-7, numbered according to the order in 
which they were first associated with the family. NPP enzymes hydrolyze a wide range of 
substrates. NPP1and NPP3 are nucleotide pyrophosphatases that cleave inorganic 
phosphate from nucleotides and their derivatives. In contrast, NPP2, NPP6 and NPP7 are 
phosphodiesterases that hydrolyze phosphodiester bonds in lysolipids and their 
derivatives. NPP4 and NPP5 are yet to be characterized in terms of substrate preference 
and biological function. Numerous lysolipid derivatives have been shown to be 
hydrolyzed by NPP2 and NPP6 but only three main lysolipid substrates have been 
previously reported for NPP7. One of the goals of this work was to characterize the 
substrate preference of NPP7 through more exhaustive kinetic means.  Our results show 
that NPP7, like NPP2 and NPP6, hydrolyzes numerous choline-containing substrates 
including glycerolipids, lysophosphatidylcholine, platelet activating factor, lyso platelet 
activating factor and the sphingolipids, sphingomyelin and sphingosylphosphorylcholine. 
A synthetic small molecule, para-nitrophenyl phosphocholine was also identified as a 
substrate for NPP7.  Like NPP6, NPP7 hydrolyzed all identified substrates with a 
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lysophospholipase C activity and like NPP2, NPP7 preferred larger lipid substrates to the 
smaller non-lipid substrates tested. 
Most hydrolytic activities of NPP isoforms lead to formation of bioactive lipids 
that affect numerous physiological and pathological processes.  This, coupled with their 
extracellular activity, makes them attractive targets for therapeutic intervention. A major 
bottleneck to their utilization as therapeutic targets is that very little is known about their 
structure and function. Although NPP enzymes hydrolyze a wide range of substrates, and 
sometimes share a common substrate, they exhibit different substrate preference profiles, 
the factors producing these substrate profiles have not been previously investigated.  Our 
second goal was therefore to employ computational modeling as a rational tool to guide 
experimental procedures in exploring NPP7 substrate specificity determinants. Our 
modeling results suggest the presence of a common binding pocket for the different 
substrate groups of NPP7and presence of essential non covalent interactions between the 
substrate and specific amino acid residues.  
Like alkaline phosphatases, NPP isoforms require two divalent metal cations 
within their catalytic core and are inactivated when the metals are removed. The amino 
acid residues that coordinate these metal cations are conserved within NPP and AP 
isoforms. However, the specific endogenous divalent metal in individual NPP isofomrs is 
not yet known. It still remains an open question as to the specific role of these divalent 
metal cations in enzyme activity. Our third goal was therefore to explore the role played 
by divalent metal cations during the NPP7 catalytic cycle. Our results indicate that the 
secondary structure of NPP7 is not altered in presence or absence of divalent metal 
cations. However, its catalytic function is eliminated with prolonged exposure to 
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sufficient amounts of metal chelators. The current work significantly advances our 
understanding of NPP7 in terms of preferred substrates, the amino acid determinants that 
underlie these preferences and the role of divalent catalytic site metal ion in the structure 





 This dissertation presents a detailed description of our efforts to better understand 
the structure and function of nucleotide pyrophosphatase/ phosphodiesterase-7 (NPP7). 
NPP7 was discovered more than 40 years ago and has been associated with a wide range 
of biological processes.  Despite its relatively long history and importance, its structure 
and function are not yet well understood.  NPP7 was choosen as the focus of this work, in 
part, because it is one of the smaller isoforms within the NPP family and could be used as 
a model for the larger isoforms that are more difficult to isolate and characterize. 
 Computational molecular modeling, molecular biology and biochemical methods 
have been used to study the structure and function of NPP7. The work in chapter 3 is an 
extensive survey of NPP7 substrates in which three new substrates were identified for the 
enzyme. This work is submitted to the Journal of Lipid Research.  Chapter 4 is a 
discussion of the use of computational homology modeling to identify substrate 
recognition determinants for NPP7 and the experimental validation of these results by 
mutagenesis and biochemical analyses. This work is submitted to the Journal of 
Molecular Pharmacology. Chapter 5 presents work on the role of divalent metal cations 
in NPP7 and was performed as a comparative survey with NPP2 and NPP6. The work is 
to be submitted as an equally authored paper by Dr. Truc Chi Pham, Irene W. Wanjala 
and Angela L. Howard to Biochemical Journal. Only work specific to NPP7 is presented 
in chapter 5 of this dissertation. To help maintain continuity, chapters 1 (introduction), 2 
(molecular biological strategies and procedures) and 5 (metal ion effects) are also 
formatted following Journal of Lipid Research guidelines.   
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1.1 NPP7 history 
 Nucleotide pyrophosphatase/ phosphodiesterase 7 is also known as alkaline 
sphingomyelinase (alk-Smase) (1-5) and was initially discovered in 1969 by Swedish 
scientist, Åke Nilsson (6). However, it remained relatively obscure for thirty years due 
to a lack of understanding of its biological relevance.  Initially, sphingomyelin (7) was 
the only known substrate and no further biological significance was associated with SM 
hydrolysis (8).  However, in the late 1990s, it was shown that sphingomyelin 
metabolism leads to the formation of both proliferative messengers such as 
lysosphingomyelin, sphingosine-1-phosphate, and ceramide phosphate and anti-
proliferative messengers such as ceramide and sphingosine (9). This revelation led to 
rejuvenated efforts toward identifying the biological significance of this enzyme. Initial 
investigations established that although NPP7 hydrolyzed sphingomyelin (SM) at 
alkaline pH, hence its name alkaline sphingomyelinase, it has no structural similarity 
with known acid and neutral sphingomyelinases (3).  In 1997, alk-SMase was shown to 
have structural and functional similarity with the NPP subfamily of alkaline 





1.2 The NPP isoforms 
  The NPP family currently consists of seven members named NPP1-7 in the order 
in which they were first associated with the family (1).  All isoforms, with the exception 
of NPP2, are membrane-anchored ectoenzymes classified as either type I or type II 
membrane proteins depending on their orientation relative to the cell membrane (1).  
NPP1 and 3 are type II (extracellular C-terminus) while NPP4-7 are type I (extracellular 
N-terminus) transmembrane proteins.   NPP2 is the only secreted member of the family 
(11).  All seven isoforms have structural and functional similarities described in the 
following sections. 
 
1.3 Structural similarities among NPP isoforms 
1.3.1  Conserved extracellular catalytic domains 
 All NPP enzymes have a modular structure with a conserved catalytic domain of 
nearly 400 amino acid residues as shown in Fig. 1.1. The different human isoforms 
exhibit 24-60% overall conserved amino acid identity (1).  In addition to the conserved 
catalytic domains, NPP4, NPP5, NPP6 and NPP7 also contain a putative N-terminal 
signal peptide and a C-terminal transmembrane domain.  Their C-termini traverse the cell 
membrane while their catalytic domains face the extracellular space (1, 12).  Functionally 
active, truncated forms of NPP6 (5) and NPP7 (13) that lack this C-terminal membrane 
anchor, termed Ex-constructs, have been described that are secreted by mammalian cells.  
NPP1 and NPP3 have N-termini that traverse the cell membrane.  Despite this reversed 
orientation, the catalytic domains of these isoforms also face the extracellular space (12). 
3 
The remaining isoform, NPP2, is synthesized as a pre-pro-enzyme that is secreted in 
active form after proteolytic processing (14).   
 
1.3.2 Nuclease-like domains and somatomedin B-like domains 
 The larger NPP isoforms, NPP1, NPP2 and NPP3, have nuclease-like domains on 
the C-terminal side of their catalytic domains. These nuclease-like domains are similar in 
primary amino acid sequence to DNA and RNA-nonspecific endonucleases but lack this 
catalytic capacity, and they lack the residues required for endonuclease activity (1).  
NPP1-3 also contain two somatomedin B-like domains that were initially thought to be 
involved in homodimerization (1).  However, the role of the somatomedin B-like 
domains in NPP isoforms remains unknown as it has now been shown that none of the 
















1.3.3 Conserved catalytic and metal-binding sites 
All seven NPP isoforms contain a single conserved nucleophilic alcohol-
containing catalytic residue (12).  In NPP6 this is a serine (5) while all other NPP family 
members contain a threonine (12).  In close proximity to the single catalytic residue are 
two divalent metal cations that are important in catalytic function. The residues 
coordinating these divalent metals are conserved in identity and spatial arrangement as 
those of other sulfo- and phospho-coordinating metalloenzymes such as alkaline 
phosphatases (12). However, the metal identity and requirement for each NPP enzyme 
are still not known.  The NPPs are believed to have a similar catalytic mechanism to that 
 
Fig. 1.1. The domain structure of the known NPP isoforms. The seven NPP isoforms are 
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of the closely related alkaline phosphatases (APs) and amino acid residues that coordinate 
the two metal cations within the catalytic site are conserved in both families of enzymes 
(12). Sequence comparisons indicate that for all NPPs, metal 1 is coordinated by two 
histidines and one aspartate while metal 2 is coordinated by two aspartates and one 
histidine. 
 
1.4 Functional similarities among NPP isoforms 
1.4.1  The catalytic cycle of NPP isoforms 
The catalytic mechanism for NPP enzymes has been proposed based on that of the 
extensively studied and closely related alkaline phosphatases (1, 12). The NPP7 catalytic 
cycle occurs in several steps as shown in Fig. 1.2. In the first step, the phosphate group of 
the incoming substrate is attacked by a metal-activated hydroxyl group of the catalytic 
residue, threonine75 (T75) in NPP7.  This leads to the formation of a phosphodiester 
linkage with the substrate phosphate resulting in a metal stabilized enzyme-substrate 
complex.  In the second catalytic step, one of the divalent metal cations activates a water 
molecule by lowering its pKa and facilitates a nucleophilic attack on the phosphate atom 
of the intermediate. This leads to regeneration of the free enzyme with the release of 

























1.4.2  NPP substrate specificity and preferences 
NPP enzymes are classified as pyrophosphatases or phosphodiesterases depending 
on the substrates they hydrolyze.  NPP1-3 are pyrophosphatases that cleave inorganic 
phosphates from nucleotides and their derivatives (17).  In contrast NPP2, NPP6 and 
NPP7 are phosphodiesterases that hydrolyze phosphodiester bonds in lipids and their 
 
Fig. 1.2. NPP7 catalytic cycle. The metal activated OH of T75 attacks the phosphate group 
of substrate (SM) in the first step. A stabilized covalent phosphorylated enzyme intermediate 
is formed.  A metal activated water molecule attacks the phosphate group leading to release 
of product generating free enzyme in the second step.  M1 and M2 are divalent metal cations 
present in the active site of all NPP enzymes (2).  
 
7 
derivatives (4, 5).  NPP4 and NPP5 are yet to be characterized in terms of substrates and 
types of activity.  NPP2 is the only one of the seven NPP isoforms that is known to 
possess both pyrophosphatase and phosphodiesterase activities (1).  As a 
phosphodiesterase it exhibits lysophospholipase D (LPLD) activity, in contrast to NPP6 
and NPP7 both of which exhibit lysophospholipase C (LPLC) activity. Fig. 1.3 illustrates 
the two types of activity using a lysophosphatidylcholine (LPC) as an example substrate.  
Beside these specific activities, NPP isoforms also exhibit differing substrate preference 
















Fig. 1.3. LPLC versus LPLD hydrolysis of LPC. NPP7 generates monoacylglycerol 
(MAG) and a phosphocholine via LPLC activity while NPP2 generates LPA and choline 
via LPLD activity. 
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1.4.3  Biological significance of NPP isoforms 
 Hydrolytic activities of the NPP enzymes affect a very diverse variety of 
biological processes as is summarized in Table 1.1. Hydrolysis of several of their 
substrates (especially lipids) generates messengers that mediate numerous signaling 
pathways to elicit these biological affects (7, 19, 20).  
 
 
Table 1.1. Summary of the properties of NPP isoforms  
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glial cell differentiation 
NPP4 N/A Unknown Unknown Unknown 


























1.5 Current studies on the characterization of NPP7  
 The biological activity of NPP7 warrants further study to better understand its 
function.  Likewise, understanding NPP7 structure and function will, by analogy, help 
understand NPP2 which is an anticancer target.  In the current study, we describe the use 
of a combination of biochemical and computational methods to significantly expand 
knowledge on the structure and function of NPP7. The following three main areas will be 
addressed.  
 
1.5.1 Influence of substrate chain length and architecture on NPP7 activity 
 An extensive investigation of the influence of substrate chain length and 
architecture within lysolipids on NPP7 catalytic function is described in Chapter 3. 
Through this work we identified two lysolipids; sphingosylphosphorylcholine (SPC) and 
lyso platelet activating factor (lyso PAF), and one synthetic small molecule, para-
nitrophenylphosphocholine (pNPPC), as novel NPP7 substrates. NPP7 activity against 
each of these newly identified substrates, as well as the previously known substrates has 
been extensively characterized using Michaelis-Menten enzyme kinetics described in 
Section 1.5.3.  
 
1.5.2 NPP7 substrate specifying determinants  
  The use of molecular modeling to investigate substrate recognition by NPP7 
and validation of the models using biochemical assays on site-directed mutant proteins is 
described in Chapter 4. Analysis of mutant activity and comparison of their efficiency 
relative to wild type enzyme was achieved by applying the Michaelis-Menten kinetics for 
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each enzyme against several NPP7 substrates. The mathematical and qualitative basis of 
the Michaelis-Menten’s theory of enzyme catalyzed reactions is briefly discussed in 
Section 1.5.3. The results obtained show that F275 is essential for recognition of all 
choline phosphodiesters by NPP7. In addition, several residues, including E169 and 
Y166, were found to play a role in determining NPP7 substrate preferences.  
  
1.5.3 Application of the Michaelis-Menten kinetics to enzyme catalysis 
 We have applied Michaelis-Menten kinetics to the characterization of the 
catalytic behavior of NPP7 and its mutants.  As such, a detailed description of the theory 
is necessary. The Michaelis-Menten (MM) theory for enzyme kinetics first assumes that 
the enzyme, E, and its substrate, S, associate reversibly to form an enzyme-substrate 




This association/dissociation is assumed to be in rapid equilibrium with Ks denoting the  
the enzyme : substrate dissociation constant (21). Therefore at equilibrium,  
  k-1 [ES] = k1[E][S]      (2) 
and 
  Ks = ([E][S])/[ES] =  k-1/ k1     (3) 
The product, P, is formed in a second step when ES yields the free enzyme plus product 
(E + P). The complete reaction equation therefore becomes; 
 
            (1) 





   
 
 After the second step, E is free to interact with another substrate molecule.  
Briggs and Haldane refined the interpretations above by assuming that the concentration 
of the enzyme-substrate complex, ES, quickly reaches a constant value in such a dynamic 
system (22). This means that ES is formed as rapidly from E + S as it disappears through 
dissociation to generate E + S and reaction to form E + P. This is the steady-state 
assumption where the change in ES concentration with time (t) is zero and is expressed as  
   d[ES]/dt =0      (5)  
With the steady state assumption the rate of formation and breakdown of ES are defined 
by rate expressions that involve several rate constants (23). A combination and 




    
The term (k-1 + k2)/k1 is defined as the Michaelis constant, Km and substituting it in 
equation (6) gives:  
  [ES] = [Et][S] / (Km + [S])     (7) 
When k2 is rate-limiting, k2 << k-1 and Km reduces to k-1 / k1, which is defined as the 
dissociation constant, Kd of the ES complex. Where these conditions hold, Km represents 
a measure of the affinity of the enzyme for its substrate in the ES complex. However, this 
        (4) 
         
           
               




    (6)
         
[Et][S]
[ES]  = 
[S]+ {(k1 +k2)/k1}
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scenario does not hold for most enzymes. In cases where k2 >> k-1 then Km= k2/k1. In 
other cases where k2 and k-1 are comparable Km remains a more complex function of all 
three rate constants. In such cases, the Michaelis-Menten equation and the characteristic 
behavior of the enzyme still apply but the Km cannot be considered as a simple measure 
of substrate affinity. 
 The Michaelis-Menten kinetics of enzyme catalyzed reactions are also 
simplified by the initial velocity assumption where formation of ES from E + P by the 
reverse reaction is ignored (24). This is true for the initial velocity for the reaction 
immediately after E and S are mixed and [P] is essentially zero. With this simplification, 
the initial velocity (Vo) is then described by the breakdown of ES to form product which 
is determined by the concentration of the enzyme-substrate complex: 
  Vo = k2[ES]       (8) 
Initial velocity can also be expressed in terms of the Michaelis constant Km as follows: 
 Vo = k2[Et][S] / (Km + [S])      (9) 
The maximal velocity, Vmax, of an enzyme occurs when the enzyme is saturated with 
substrate i.e. when [ES] = Et, and can thus be described as k2[Et]. Therefore equation 9 
can also be expressed as:   
  Vo = Vmax [S] / (Km + [S])              (10) 
This is known as the Michaelis-Menten equation, the rate equation for a one-substrate 
enzyme–catalyzed reaction. This equation is a statement of the qualitative relationship 
between the initial velocity Vo, the maximal velocity Vmax and the substrate concentration 
[S], all related through the Michaelis constant Km.  Km is expressed in units of 
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concentration and is described as the concentration of substrate when the initial velocity, 
Vo equals half the maximal velocity: 
   Km = [S], when Vo = 1/2Vmax    (11) 
In the work described in Chapters 3 and 4 of this dissertation, enzyme activity was 
measured either by fluorescence (lipid substrates) or absorbance (paranitrophenol 
derivative substrates). NPP7 catalytic activity against varying substrate concentrations 
was measured in relative fluorescence and absorbance units which were converted to 
product concentrations using standard curves based on resorufin and para-nitrophenol, 
respectively. The initial velocity (Vo) of the enzyme was determined by taking the slope 
(within the linear range) of the activity curve for each substrate concentration. The linear 
fit equation from a plot of signal (fluorescence or absorbance) against standard (resorufin 
or para-nitrophenol) concentration was used to convert all relative fluorescence and 
absorbance units to product concentrations.  The resulting initial reaction velocities were 
plotted against substrate concentration and rectangular hyperbolic curve fitting [y = m1 * 
m2x(1+ m2x)] was done with KaleidaGraph 4.0 (Synergy software, Reading, PA, USA). 
In this equation, m1 = Vmax and 1/m2 = Km. 
 To describe the limiting rate of any enzyme-catalyzed reaction at saturation, a 
more general rate constant, kcat is used (23). If the enzyme-catalyzed reaction has several 
steps and one is clearly rate-limiting, then kcat is equivalent to the rate constant for that 
limiting step (25). When several steps are partially rate-limiting, kcat can become a 
complex function of several of the rate constants that define each individual step. In the 
Michaelis-Menten equation, kcat = Vmax / [Et] and equation 10 thus becomes 
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  Vo = kcat[Et][S] / (km + [S])     (12) 
kcat is also called the turnover number and it is equivalent to the number of substrate 
molecules converted to product in a given unit time by a single enzyme active site when 
the enzyme is saturated with substrate. The first order rate constant, kcat and has units of 
reciprocal time. The kinetic parameters, kcat and Km, are useful in studying and comparing 
different enzymes. Each enzyme will have values of kcat and Km that reflect the cellular 
environment such as the concentration of substrate normally encountered in vivo by the 
enzyme and the chemistry of the reaction being catalyzed. In the results described herein, 
the turnover number (kcat) was calculated by dividing the Vmax value by the final enzyme 
concentration used in all assays (8.33 nM). This value represents the number of catalytic 
cycles or turnovers per enzyme active site per unit time when enzyme is saturated with 
substrate (22). The kinetic parameters, kcat and Km also allow the evaluation of the kinetic 
efficiency of enzymes although either parameter alone is insufficient for this task. For 
instance, two enzymes catalyzing different reactions may have the same kcat value yet the 
rates of the uncatalyzed reactions may be different and thus the rate enhancements 
brought about by the enzymes may be greatly different (22). The best way to compare 
catalytic efficiencies of different enzymes or turnover of different substrates by the same 
enzyme is to compare the ratio kcat / Km for the two reactions. This ratio is also called the 
specificity constant (23) and is the rate constant for the conversion of E + S to E + P. 
When [S] << Km equation 12 reduces to the form 
  Vo = kcat / Km [Et][S]      (13) 
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Vo in this case depends on the concentration of two reactants, [Et] and [S] making kcat /Km 




. The higher the ratio, the more efficient 
the enzyme is for a given substrate (21) however, there is an upper limit to kcat / Km, 
imposed by the rate at which E and S can diffuse together in aqueous environment. The 










.  Enzymes that have a specificity constant 
value near this range are said to have achieved catalytic perfection. In this dissertation, 
we shall use all these parameters to characterize the catalytic activity of NPP7 and its 
mutants against several substrates. 
 
1.5.4 The role of divalent metals in NPP7 catalytic function 
 The role of divalent metal cations in NPP7 catalytic function is described in 
Chapter 5.  We have employed both functional (biochemical assays) and structural 
(circular dichroism) methods to investigate NPP7 behavior in the presence and absence of 
divalent metal cations.  Although previous reports indicated that EDTA is necessary for 
NPP7 catalytic activity, our findings indicate the opposite is true.  In fact, we successfully 
used EDTA to significantly reduce the catalytic function of NPP7.  Addition of 
biologically relevent divalent metals (cobalt, zinc, and nickel) to the inactivated enzyme 
restored catalytic activity.  In all cases the secondary structure of EDTA and metal ion 
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GENETIC ENGINEERING, SUB-CLONING, PROTEIN EXPRESSION AND 
PURIFICATION OF HUMAN NPP7 
 
This project required the ability to express small amounts of wild type and site-
directed mutants of NPP7 for activity determination, as well as the ability to express and 
purify larger amounts of native enzyme for biochemical, structural and functional 
characterization.  To accomplish these diverse goals we utilized two complementary 
systems, transient transfection in mammalian cells (HEK293) and baculovirus expression 
in insect cells (Sf9).  The rationale and methodology used to generate functional enzyme 




DNA encoding full length, human NPP7 (Genebank number AY20633) was 
generously provided by Dr. Rui-Dong Duan (Lund University, Lund, Sweden). This gene 
was supplied in the pcDNA 4/TO/myc–his B mammalian expression vector cloned 
between KpnI and NotI restriction sites (Fig. 2.1).  The work described herein for NPP7 
is part of a larger project to characterize lysophospholipid preferring NPP isoforms.  
Thus, the NPP7 expression plasmid provided was modified prior to subcloning to achieve 
several goals common to the overall project.  First, changes were made to the cloning 
sites so that a single insert could be subcloned into both the desired mammalian 
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expression vector (pcDNA3.1(+)) and baculovirus transfer vector (pFASTBac1).  
Second, a stop codon was inserted after residue 415 (threonine) to remove the 41 C-
terminal residues including the transmembrane anchor to generate a soluble version of the 
protein that could be collected from conditioned cell culture medium.  Finally, a FLAG 
affinity tag (DYKDDDDK) was inserted downstream of the protein sequence (between 
T415 and the stop codon) to allow for easy purification. The protein expressed from the 
resulting modified insert was a shortened version of the human NPP7 enzyme that was 
truncated after the FLAG affinity tag during expression.  This modified protein was 
referred to as NPP7ExFLAG owing to its extracellular (Ex) localization, as well as the 
presence of the FLAG affinity tag.  A similarly truncated NPP construct was previously 







2.2 Genetic Engineering 
All site-directed mutations and PCR insertions were accomplished using the 
QuickChange PCR kit (Stratagene, La Jolla, CA, USA) according to the manufacturer’s 
protocols.  The KpnI site (GGTACC) in the parent vector was mutated to a BamH I 
recognition sequence (GGATCC) using the sense primer 5’-GCGTTTAAACTTAAG 
CTTGGATCCGAAATGAGAG-3’ and antisense primer 5’-CTCTCATGCTTTCG 
GATCCAAGCTTAAGTTTAAACGC-3’.  In a separate PCR reaction, the FLAG 
 
Fig. 2.1. NPP7ExFLAG genetic engineering scheme.  Full length human NPP7 was 
provided in the pcDNA4/TO/myc-hisB plasmid (left) cloned between Kpn1 and Not1 
restriction sites.  Final constructs for NPP7 transient transfection into mammalian cells 
(pcDNA3.1+, top right) and baculovirus-mediated infection of insect cells (pFASTBac1, 
bottom right).  Empty vectors for pcDNA3.1+ (top middle) and pFASTBac1 (bottom 
middle) show the relative orientation of Kpn1, BamH1 and Not1 restriction sites.    
22 
affinity-tag (DYKDDDDK) and a stop codon were incorporated at position 416 using the 
sense primer 5’-CCCATGCTGCACACAGACTACAAGGACGACGATGACAAGTAG 
GAATCTG CTCTTCCG-3’ and antisense primer 5’-CGGAAGAGCAGATTCCT 
ACTTGTCATCG TCGTCCTTGTAGTCTGTGTGCAGCATGGG-3’.  Plasmids were 
isolated from ampicillin resistant colonies using Miniprep kits from Qiagen (Valencia, 
CA, USA) according to the manufacturer’s protocols and were verified by complete 
nucleotide sequencing of the insert.  Fig. 2.2 shows complete amino acid sequences for 
the parent, full length NPP7 insert and for the modified truncated FLAG fusion protein. 
 
 
Human NPP7(wild type) 
MRGPAVLLTV ALATLLAPGA GAPVQSQGSQ NKLLLVSFDG FRWNYDQDVD  
TPNLDAMARD GVKARYMTPA FVTMTSPCHF TLVTGKYIEN HGVVHNMYYN 
TTSKVKLPYH ATLGIQRWWD NGSVPIWITA QRQGLRAGSF FYPGGNVTYQ 
GVAVTRSRKE GIAHNYKNET EWRANIDTVM AWFTEEDLDL VTLYFGEPDS 
TGHRYGPESP ERREMVRQVD RTVGYLRESI ARNHLTDRLN LIITSDHGMT 
TVDKRAGDLV EFHKFPNFTF RDIEFELLDY GPNGMLLPKE GRLEKVYDAL 
KDAHPKLHVY KKEAFPEAFH YANNPRVTPL LMYSDLGYVI HGRINVQFNN 
GEHGFDNKDM DMKTIFRAVG PSFRAGLEVE PFESVHVYEL MCRLLGIVPE 




MRGPAVLLTV ALATLLAPGA GAPVQSQGSQ NKLLLVSFDG FRWNYDQDVD  
TPNLDAMARD GVKARYMTPA FVTMTSPCHF TLVTGKYIEN HGVVHNMYYN 
TTSKVKLPYH ATLGIQRWWD NGSVPIWITA QRQGLRAGSF FYPGGNVTYQ 
GVAVTRSRKE GIAHNYKNET EWRANIDTVM AWFTEEDLDL VTLYFGEPDS 
TGHRYGPESP ERREMVRQVD RTVGYLRESI ARNHLTDRLN LIITSDHGMT 
TVDKRAGDLV EFHKFPNFTF RDIEFELLDY GPNGMLLPKE GRLEKVYDAL 
KDAHPKLHVY KKEAFPEAFH YANNPRVTPL LMYSDLGYVI HGRINVQFNN 
GEHGFDNKDM DMKTIFRAVG PSFRAGLEVE PFESVHVYEL MCRLLGIVPE 
ANDGHLATLL PMLHTDYKDD DDK 
 
Fig. 2.2.  Amino acid sequences for full length NPP7 and truncated 
NPP7ExFLAG.  The catalytic residue T75 is highlighted in black and the FLAG 
affinity sequence is highlighted in grey. 
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2.3 Mammalian cell expression 
Mammalian protein expression was used to generate relatively small amounts of 
wild type and mutant, human NPP7ExFLAG protein for in vitro functional analysis. 
 
2.3.1 Subcloning of NPP7ExFLAG into pcDNA 3.1(+)  
The modified human NPP7ExFLAG insert was subcloned from the parental 
pcDNA 4/TO/myc–his B vector into pcDNA3.1(+)  (Invitrogen, Carlsbad, CA, USA) 
using standard molecular biology techniques.  Inserts were liberated using double 
digestions with BamH1 and Not1 (New England Biolabs, Ipswich, MA, USA), purified 
by Qiagen’s gel extraction protocol  (Valencia, CA, USA), and ligated into target vector 
that had been digested with BamH1 and Not1 using T4 DNA ligase (New England 
Biolabs, Ipswich, MA, USA).  Plasmids were isolated from ampicillin-resistant colonies 
using Miniprep kits from Qiagen (Valencia, CA, USA) according to the manufacturer’s 
protocols and were verified first by agarose gel electrophoresis of NotI and BamHI 
double digests and finally by complete nucleotide sequencing of the insert (data not 
shown). 
 
2.3.2 NPP7ExFLAG expression in HEK293 cells 
Expression of human NPP7ExFLAG protein and site directed mutants was done 
by transient transfection in human embryonic kidney (HEK293T) cells using the Polyfect 
transfection reagent (Qiagen, Valencia, CA, USA) according to the manufacturer’s 
protocols.  Briefly, HEK293T cells were seeded in Dulbecco’s Modified Eagle’s Medium 
(DMEM) containing 10% heat inactivated fetal calf serum and 2 mM L-glutamine and 
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100 U/ml penicillin/streptomycin.  The cells were grown overnight at 37
o
C and 5% CO2 
to 80% confluence before transfection with the appropriate NPP7-pcDNA3.1(+) construct 
and polyfect reagent.  Eight hours after trasfection, the culture medium was changed to 
serum-free DMEM, and cells were incubated for an additional 48 hours. Conditioned 
medium containing secreted NPP7ExFLAG protein was collected and concentrated using 
Centricon 10,000 molecular weight cutoff filters (Millipore, Billerica, MA, USA) by 
centrifugation at 3,073 x g for 20 minutes at 4°C. Expression of protein was verified by 
Western blot (detailed protocols can be found in section 2.3.3).  Concentrated protein was 
buffer-exchanged three times into NPP7 assay buffer (10 mM Tris-HCl, 150 mM NaCl, 
10 mM taurocholate  pH 8.0) using Centricon 10,000 molecular weight cutoff filters 
(Millipore, Billerica, MA, USA) by centrifugation at 3,073 x g for 20 minutes at 4°C.  
Proteins were stored as 0.5-1.0 µM stocks at 4
o
C without the addition of adjuvants or 
preservatives prior to functional characterization (see discussion in section 2.5). 
 
2.3.3 Verification of NPP7ExFLAG expression 
Western blots with the Anti-FLAG M2 antibody (Sigma-Aldrich, St. Louis, MO, 
USA) were used to verify protein expression of NPP7ExFLAG and its mutants in 
conditioned media of transiently transfected HEK293T cells.  Following separation of 
proteins using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
on 4-15% gradient gels (Bio-Rad, Hercules, CA, USA), proteins were transferred to 
polyvinylidene difluoride (PVDF) membranes (Bio-Rad, Hercules, CA, USA) by 
electroblotting at 100V in Tris/Glycine buffer containing 1% SDS and 20% methanol for 
1 hour.  Nonspecific binding sites were blocked using Tween containing 50 mM Tris 
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buffered saline (TBST) (2.7 mM KCl, 138 mM NaCl, 0.5% (v/v) Tween
®
20 and 5% 
(w/v) non-fat dry milk (NFDM).  After appropriate washes, the membrane was treated 
with Anti-FLAG M2 antibody (Sigma-Aldrich, St. Louis, MO, USA) (1:2000 dilution in 
TBST + 3% NFDM).  Following additional washes, the membrane was treated with goat 
anti-mouse IgG antibody (Sigma-Aldrich, St. Louis, MO, USA) (1:5000 dilution in 
TBST + 3 % NFDM). After a final wash, SuperSignal Pico West chemiluminescent 
substrate (ThermoScientific, Rockford, IL, USA) was used in conjunction with a digital 
imaging system (Fotodyne, Hartland, WI, USA) for detection. Fig. 2.3 shows a sample 












2.4 Baculovirus expression of NPP7ExFLAG 
Baculovirus expression was used to generate large amounts of wild type protein 
for structural and functional characterization.  Previous research established that NPP7 is 
a glycoprotein that lacks activity in the absence of glycoslylation (2, 3).   Although insect 
 
Fig. 2.3 Sample Western blot image for NPP7 expression verification.  
Three different concentrations (2X, 3X and 5X) of each protein sample were 






















































cells lack the ability to perform the complete array of complex glycosylation available in 
mammalian cells, they do have the ability to perform simple glycosylation, as well as the 
ability to perform other post-translational modifications possible in mammalian systems  
(4, 5).  Here we chose to use the Bac-to-Bac baculovirus expression system (Invitrogen, 
Carlsbad, CA, USA) and Sf9 insect cells.   
 
2.4.1 Subcloning NPP7ExFLAG into pFastBac1  
The Kpn1 and Not1 restriction sites present in the parent vector had a reversed 
orientation to those in the pFastBac1 transfer vector as shown in Figure 2.1. As was 
described in sections 2.1 and 2.2, the Kpn1 site was mutated to a BamH1 recognition 
sequence which solved this issue. The NPP7ExFLAG insert was subcloned into 
pFASTBac1 in parallel with pcDNA3.1(+) using the same protocols described in section 
2.3.1.  Bacmid was prepared according to the manufacterer’s protocols.  Briefly, after 
successful subcloning to generate the pFastBac-NPP7ExFLAG plasmid, the system 
required the introduction of a viral expression construct into the pFastBac1 donor vector. 
Bacmid DNA is a baculovirus shuttle vector contained in specialized DH10Bac™ E. coli 
(Invitrogen, Carlsbad, CA, USA), which also contain a low-copy number mini-F 
replicon, kanamycin resistance marker, LacZ gene and a helper plasmid.  All of these 
components are required to transpose the Tn7 element from the pFastBac donor plasmid 
to the mini-attTn7 attachment site on the bacmid to generate a recombinant bacmid (4-7).  
The resulting recombinant bacmid DNA was purified using the PureLink HiPure Plasmid 
Maxiprep Kit (Invitrogen, Carlsbad, CA, USA) with subsequent verification by PCR 
(data not shown). 
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2.4.2 NPP7ExFLAG expression in Sf9 insect cells 
Sf9 insect cells were seeded in 6-well plates at a density of 9 x 10
5
 cells per well 
in 2 ml of Sf-900 III serum free medium (Invitrogen, Carlsbad, CA, USA) supplemented 
with 50 µg/mL streptomycin and 50 units/mL penicillin (complete growth medium). The 
cells were incubated at 27°C and allowed to attach to the bottom of the wells for 1 hour.  
Transfection complexes were prepared using 2 µg bacmid DNA and 9 mL Cellfectin 
transfection reagent (Invitrogen, Carlsbad, CA, USA) diluted in 100 mL of 
unsupplemented Grace’s medium (Invitrogen, Carlsbad, CA, USA). The complexes were 
gently mixed and incubated at room temperature for 30 minutes.  Cells were incubated 
with the complexes at 27°C for 5 hours after which the DNA/lipid complexes were 
removed and replaced with 2 mL of complete growth medium.  Following incubation at 
27°C for 144 hours, a P1 viral stock resulted. To isolate the P1 viral stock, the 
conditioned cell culture medium was collected and centrifuged at 500 x g for five 
minutes. The clarified supernatant was then transferred to fresh sterilized tubes, and FBS 
was added up to a concentration of 2%. The viral stocks were stored at 4°C protected 
from light for up to 2 months.  
The P1 viral stock was amplified to a higher titer P2 stock using fresh Sf9 cells. 
Sf9 cells were seeded in 6-well plates at a density of 9 x 10
5
 cells per well in 2 mL of Sf-
900 III serum free medium supplemented with 50 µg/mL streptomycin and 50 units/mL 
penicillin (complete growth medium). The cells were incubated at 27°C and allowed to 
attach to the bottom of the wells for one hour. 50 µL of P1 viral stock were added, and 
the cells were incubated at 27°C for 144 hours to generate P2 viral stocks.  
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To express large amounts of human NPP7ExFLAG protein, Sf9 cells were 
amplified in suspension culture (27°C with orbital shaking at 140 rpm) up to 1 liter in a 3 
liter flask.  Cells were grown in suspension up to a density of 2 x 10
6
 cells/ mL of 
medium before infection with 15 mL of P2 viral stock.  Following infection, cells were 
incubated at 27°C with shaking at 140 rpm for 72 hours for protein expression. After 72 
hours, the conditioned medium was collected and centrifuged at 3,073 x g for 10 minutes 
to harvest NPP7ExFLAG. The supernatant was filtered using sterile filtering cups before 
protein purification using an Anti-FLAG affinity column (described in section 2.4.3). 
 
2.4.3 Affinity purification of NPP7ExFLAG expressed in sf9 cells 
Secreted NPP7ExFLAG protein was purified from conditioned cell culture 
medium from baculovirus infected Sf9 cells by affinity chromatography using Anti-
FLAG M2 agarose beads (Sigma-Aldrich, St. Louis, MO, USA).  Clarified conditioned 
medium was passed over an Anti-FLAG M2 Gel affinity column (5 mL column volume, 
Sigma-Aldrich, St. Louis, MO, USA) equilibrated in TBS buffer (50 mM Tris-HCl, 150 
mM NaCl, pH 7.4). Bound protein was washed with 20 column volumes of TBS and then 
eluted with TBS containing 50 µg/mL FLAG peptide. The purified protein was 
concentrated using Centricon 10,000 molecular weight cutoff filters (Millipore, Billerica, 
MA, USA) by centrifugation at 3,073 x g for 20 minutes at 4°C.  The concentrated 
protein was buffer exchanged into 10 mM Tris-HCl, 10 mM NaCl, pH 7.4 and stored at 
4°C without addition of adjuvants or preservatives (see discussion in section 2.5).  After 
purification, protein expression was verified by SDS-PAGE on 4-15% gradient gels (Bio-
Rad, Hercules, CA, USA), as shown in Fig. 2.4. The purified protein is truncated after 
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residue 415 (threonine) and the FLAG sequence and has a molecular mass of 
approximately 50 kDa, as opposed to the 60kDa molecular mass for the full length 
enzyme. It is also noteworthy that the total mass obtained by the sum of all amino acids 
including the FLAG-tag is about 48 kDa, but the band obtained on SDS-PAGE is slightly 
above 50 kDa, most likely due to post-translational modification(s). Mature human NPP7 
is known to be glycosylated at five positions (1) and insect cells are capable of such post-

















2.5 Storage of expressed protein 
In parallel work on the NPP2 isoform, it was determined that 20% ethylene glycol 
was required to stabilize purified enzyme stocks for storage.  The use of preservatives 
 
Fig. 2.4. SDS-PAGE of affinity purified NPP7ExFLAG. Flow-through fractions 
were collected after protein binding onto the column. Elution fractions were collected 
using 5ml aliquots of FLAG peptide. Regeneration fractions were collected with 5ml 





















and/or adjuvants during storage of NPP7 had not been previously reported in the 
literature. Thus, we examined the effect of several adjuvants including ethanol, 2-methyl-
2,4-pentanediol (MPD), and ethylene glycol (EG) (8) on the stability of purified NPP7 
stocks.  All three adjuvants tested resulted in interference with assays to assess NPP7 
function. In contrast, samples of NPP7 stored without additives remained stable and fully 
active for more than two months at a minimum concentration of 0.5 μM when stored at 
4°C in NPP7 assay buffer (50 mM tris-HCl 150 mM NaCl, pH 8.0) or circular dichroism 
(CD) buffer (10 mM tris-HCl, 10 mM NaCl, pH 7.4).  Working stocks (25 nM enzyme) 
were prepared immediately prior to use for all activity assays.  
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THE INFLUENCE OF SUBSTRATE CHAIN LENGTH AND ARCHITECTURE 
ON NPP7 CATALYTIC FUNCTION 
 
3.1 Abstract 
Nucleotide pyrophosphatase/phosphodiesterase (NPP) 7 is a member of the NPP 
family of ectoenzymes. The NPP family consists of seven known isoforms that have been 
associated with a wide range of biological effects. NPP7 was discovered 40 years ago but 
slow progress has been made toward its structural and functional characterization. It has 
previously been shown to hydrolyze three lipid substrates, lysophosphatidylcholine, 
platelet activating factor, and sphingomyelin. NPP7 activity against these three substrates 
has been associated with human diseases including cancer, atherosclerosis, and 
inflammatory bowel disease. In this study, we identify additional NPP7 substrates and 
characterize the effect of substrate chain length and architecture on their hydrolysis 
through kinetic analysis. Two bioactive lipids (sphingosylphosphorylcholine and lyso 
platelet activating factor) and one synthetic small molecule (para-
nitrophenylphosphocholine) were identified as novel NPP7 substrates. A new 
absorbance-based assay method using the identified synthetic substrate is also described.  
 
3.2 Introduction 
 Nucleotide pyrophosphatase/ phosphodiesterase 7 (NPP7) has previously been 
shown to hydrolyze three endogenous lipid substrates, lysophosphatidylcholine (LPC), 
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platelet activating factor (PAF), and sphingomyelin (SM) with a lysophospholipase C 
activity (1).  NPP7 is localized mostly to the GI tract (2) and its activity leads to 
generation of signaling messengers implicated in various biological processes associated 
with this organ system (1). The hydrolysis of SM is important in the breakdown and 
absorption of dietary SM, maturation of the intestinal tract and cholesterol absorption (3). 
Hydrolysis of PAF is thought to play a role in suppression of PAF-induced inflammation 
in the intestinal tract (4).  The hydrolysis of LPC by NPP7 reduces the generation of LPA 
by distinct lysophospholipase D enzymes and likely plays a role in decreasing cancer risk 
(5).  NPP7 is an enzyme with a growing biology that merits understanding in terms of 
structure and function.  Unfortunately, the substrate profile of NPP7 is limited to these 
three known substrates without complete kinetic characterization.  Unlike NPP2 (6) and 
NPP6 (7), the other known lysolipid preferring phosphodiesterases of the NPP family, a 
detailed survey of possible substrates has not been published for NPP7.  Such a study 
would help elucidate structure–activity relationships to help better understand the 
functions of this enzyme.   
  In the current study, a survey of possible lysolipid substrates of NPP7 has been 
conducted. Substrate candidates were selected with varied chain lengths, linkage 
functionality, and linker region. All candidates were subjected to full kinetic analysis of 






3.3 Materials and Methods 
3.3.1 NPP7 plasmid design 
The gene coding for full length, human NPP7 contained within the pcDNA 
4/TO/myc–his B mammalian expression vector was generously donated by Dr. Rui-Dong 
Duan of Lund University (Lund, Sweden).  The insert originally contained Kpn1 
(upstream) and Not1 (downstream) cloning sites.  To make this insert compatible with the 
pFASTBac1 vector, the KpnI site (GGTACC) in the parent vector was mutated to a 
BamH I recognition sequence (GGATCC) using the sense primer 5’-GCGTTTAAAC 
TTAAGCTTGGATCCGAAATGAGAG-3’ and antisense primer 5’-CTCTCATGCTT 
TCGGATCCAAGCTTAAGTTTAAACGC-3’. In a separate PCR reaction the FLAG 
affinity-tag (DYKDDDDK) and a stop codon were incorporated at amino acid position 
416 using the sense primer 5’-CCCATGCTGCACACAGACTACAAGGACGACG 
ATGACAAGTAGGAATCTGCTCTTCCG-3’ and antisense primer 5’-
CGGAAGAGCAGATTCCTACTTGTCATCGTCGTCCTTGTAGTCTGTGTGCA 
GCATGGG-3’. The Quickchange PCR kit (Stratagene, La Jolla, CA, USA) was used for 
all mutagenesis according to the manufacturer’s protocols.  All mutants were verified 
through complete nucleotide sequencing before further manipulation.  Truncation of 
NPP7 at amino acid position 416 (to generate the construct NPP7ExFLAG) has 
previously been shown to generate functional, extracellularly localized protein (8).  To 
allow for high capacity protein production and purification, the NPP7ExFLAG insert was 
used to generate a recombinant bacmid using the Bac-to-Bac system (Invitrogen, 
Carlsbad, CA, USA) according to the manufacturer’s protocols. Bacmid DNA was 
purified using the PureLink HiPure Plasmid Maxiprep Kit (Invitrogen K2100-06, 
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Carlsbad, CA, USA) and verified by PCR.  Recombinant Bacmid DNA was transfected 
into Sf9 cells in the presence of Cellfectin transfection reagent (Invitrogen, Carlsbad, CA, 
USA) to generate viral stocks.  High titer viral stocks were obtained after a second 7 day 
infection. 
 
3.3.2 NPP7 protein expression and purification 
For protein expression, Sf9 cells were amplified to a density of 2 x 10
6 
cells/mL in 
a 1L cell culture suspension before the addition of high titer viral stock (15 mL). After 72 
hours of infection, conditioned medium was collected and clarified by centrifugation at 
3,073 x g for 10 minutes.  The supernatant was filtered using 0.22 μm sterile filtering 
cups (Millipore, Billerica, MA, USA) before protein purification.  
 The filtered media was purified using an Anti-FLAG M2 Gel affinity column 
(Sigma-Aldrich, St. Louis, Mo, USA) equilibrated in TBS buffer (50 mM Tris, 150 mM 
NaCl, pH 7.4).  Bound proteins were washed with 20 column volumes of TBS and then 
eluted with TBS containing 500 μg/mL FLAG peptide (Sigma-Aldrich, St. Louis, MO, 
USA). Purified proteins were concentrated and buffer exchanged into 10 mM Tris, 10 
mM NaCl, pH 7.4 using Centricon 10,000 MWCO filters (Millipore, Billerica, MA, 
USA).  Protein purity was verified by SDS-PAGE with Coomassie staining and Western 
blot.  
 
3.3.3 NPP7 catalytic activity assays 
Fluorescence-based assay: Hydrolysis of all lipid substrates was monitored using 
a modification of Invitrogen’s Amplex Red phospholipase C assay to detect released 
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phosphatidylcholine. NPP7ExFLAG catalytic activity was monitored via fluorescence 
determination (excitation 571 nm and emission 585 nm) every minute for 1 hour using a 
Synergy2 multiwell plate reader (BioTek Instruments Inc., Vermont, USA).  Each well 
on the plate was loaded with a total of 60 μL consisting of substrate, Amplex Red 
cocktail (10 μM Amplex Red reagent, 0.1 U/mL choline oxidase, 1 U/mL horseradish 
peroxidase, 4 U/mL alkaline phosphatase) and recombinant, purified NPP7ExFLAG 
(8.33 nM). All components were prepared in NPP7 assay buffer containing 50 mM Tris-
HCl, pH 8.0, 150 mM NaCl, and 10 mM sodium taurocholate (2) without the previously 
described 2 mM EDTA. 
 Absorbance-based assay: Hydrolysis of all synthetic, para-nitrophenol 
containing substrates was done using an absorbance assay based on the para-
nitrophenolate product that has a maximum absorbance at 405 nm. Each well on the plate 
was loaded with a total of 60 µL consisting of substrate and enzyme in NPP7 assay 
buffer.  NPP7ExFLAG activity was monitored by the level of absorbance at 405 nm for a 
1 hour period using a Synergy2 multiwell plate reader (BioTek Instruments Inc., 
Vermont, USA). 
 
3.3.4 Calculation of kinetic parameters 
 NPP7 catalytic activity against varying substrate concentrations was measured in 
relative fluorescence and absorbance units which were converted to product 
concentrations using standard curves based on resorufin and para-nitrophenol, 
respectively. The initial velocity of the enzyme-catalyzed reaction was determined by 
taking the slope (within the linear range) of the activity curve for each substrate 
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concentration. The linear fit equation from a plot of signal (fluorescence or absorbance) 
against standard (resorufin or para-nitrophenol) concentration was used to convert all 
relative fluorescence and absorbance units to product concentrations.  The resulting initial 
reaction velocities were plotted against substrate concentration and rectangular 
hyperbolic curve fitting [y = m1 * m2x(1+ m2x)] was done with KaleidaGraph 4.0 
(Synergy software, Reading, PA, USA). In this equation, m1 = Vmax and 1/m2 = Km. The 
turnover number (kcat) was calculated by dividing the Vmax value by the final enzyme 
concentration used in all assays (8.33 nM). This value represents the number of catalytic 
cycles or turnovers per enzyme active site per unit time when enzyme is saturated with 
substrate (9). We further calculate the enzyme’s catalytic efficiency for each substrate 
hydrolyzed using kcat/Km ratio. The higher the ratio, the more efficient the enzyme is for a 
given substrate (10).  
 
3.4 Results 
3.4.1 Expression and purification of human NPP7ExFLAG 
 The expression and localization of human NPP7 in Sf9 insect cells was analyzed 
at 48, 72, and 96 hours after infection with high titer baculoviorus stocks by Western blot 
as shown in Fig. 3.1A.  The majority of the expressed protein was localized within the 
cell pellet but a significant minority was localized to the less complex concentrated 
conditioned medium (CCM)   For the experiments outlined herein, only that material 
localized to the CCM was purified by anti-FLAG affinity chromatography and used for 
enzyme assays (Fig. 3.1B). The truncated NPP7ExFLAG protein band has a predicted 
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molecular weight of 48 kDa but the protein bands appear slightly above 50 kDa probably 





3.4.2 Effect of EDTA on NPP7 activity 
 Previously, Duan et al. suggested that zinc inhibited NPP7 activity and that EDTA 
reversed this effect (2).  These results are difficult to rationalize based on the knowledge 
that NPP7, like all NPP isoforms, is a metalloenzyme (11) that is presumed to require 
divalent metals in its active site for catalytic activity.  We have recently shown that 
EDTA is an effective inhibitor of all known lysolipid preferring NPP isoforms (Pham et 
al., manuscript in preparation).  Here we show that treatment with EDTA at 2 mM 
A      B 
 
Fig. 3.1. Western blot of NPP7ExFLAG  expressed in sf9 cells.  (A). Trial expressions 
were performed to obtain the optimal expression time in Sf9 insect cells. The amount of 
truncated NPP7ExFLAG secreted in the medium was analyzed after 48, 72, and 96 hours. 
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significantly blocks NPP7ExFLAG activity using the substrates LPC (16:0), PAF (16:0), 
and SM (Fig. 3.2). This figure shows single concentration data at a single assay time 
















3.4.3 Hydrolysis of SM and SPC 
 Fig. 3.3 shows Michaelis-Menten plots of initial velocity versus substrate 
concentration for NPP7ExFLAG mediated hydrolysis of both SM and SPC using the 
Amplex Red fluorescence method as described in materials and methods.  A panel of 
kinetic parameters determined experimentally for the hydrolysis of SM and SPC are 
 
Fig. 3.2. Effect of EDTA on NPP7ExFLAG catalytic activity. Hydrolysis of 
PAF16:0, LPC16:0 and SM by 8.33nM NPP7 was analyzed using the Amplex Red 
assay, in the presence (black bars) and absence (white bars) of 2 mM EDTA in the 



















shown in Table 3.1. The Km values of 23 ± 1.3 μM for SM and 56 ± 1.4 μM for SPC 
indicate a 2.4-fold greater affinity for SM by NPP7ExFLAG.  The maximal velocity 
(Vmax) and the relative turnover number (kcat) for hydrolysis of SPC were approximately 
10% higher than SM.  Based on these data the calculated specificity constant (kcat/Km) for 
SM was twice that of SPC meaning that NPP7 exhibits a higher catalytic efficiency 
























Fig. 3.3. Hydrolysis of SM and SPC by NPP7ExFLAG. (A). Varying concentrations of SM and 
SPC were used to obtain initial velocities using the Amplex Red assay. Plots of substrate 
concentration versus initial velocity were generated using the KaleidaGraph software package.  The 
equation of each nonlinear curve, y= m1m2x/(1+m2x),  was used to obtain values for Km and Vmax 
for each substrate (Table 3.1). Final values were obtained from the average of three triplicate runs. 
Both SM and SPC have the basic structure shown in panel B.  
 
R is a 15 carbon alkyl chain for both SM and SPC

























Table 3.1. Kinetic parameters for the hydrolysis of SM and SPC. 








SM 23 ± 1.3 3.3 ± 0.1 3.9 ± 0.11 17.0 ± 5.8 
SPC 56 ± 1.4 3.6 ± 0.02 4.3 ± 0.02 8.0 ± 2.6 
 
 
3.4.4 Hydrolysis of LPC 
 Plots of initial velocity versus substrate concentration for NPP7ExFLAG 
mediated hydrolysis of LPC species are shown in Fig. 3.4A.  Summaries of kinetic 
parameters obtained for each LPC species are compiled in Table 3.2.  GPC, the smallest 
LPC species (where the sn-1 fatty acid has been replaced with a hydrogen), had the 
smallest Km value of 25 μM but its turnover number (kcat) was at least eight times less 
than the other LPC species examined.  LPC14:0, LPC16:0 and LPC18:0 had similar 
affinities (Km = 38 μM, 41 μM and 33 μM, respectively) and a one way ANOVA 
statistical analysis followed by the Bonferroni’s post test showed no significant 
difference in the Km values for these three substrates. LPC14:0 had a slightly larger kcat 
value of 2.1 sec
-1
 compared to that of LPC16:0 and LPC18:0 (1.6 sec
-1 
for both). The 
kcat/Km values (5.5 x 10
4
, 4.0 x 10
4






 for LPC14:0, LPC16:0, and 
LPC18:0, respectively) show that NPP7 hydrolyzed LPC14:0 more effectively.  The 
specificity constants for LPC14:0 and LPC16:0 were statistically different with a p value 
of <0.0001. For the shorter chain lengths of LPC tested (LPC10:0 and LPC12:0), the rate 
of hydrolysis decreased with decreasing chain length as shown by the kinetic parameters. 
LPC10:0 had the highest Km value of 371 μM and a specificity constant six times smaller 























A       B  
 
Fig. 3.4. Hydrolysis of LPC by NPP7ExFLAG. Glycerophospholipids of varying chain length and 
linker functionality were used to obtain initial velocities with 8.33 nM of NPP7ExFLAG. Panel A is 

















































3.4.5 Hydrolysis of PAF and lysoPAF  
 PAF16:0 has previously been shown to be a substrate for NPP7 (4).  Here a 
complete kinetic analysis of NPP7ExFLAG mediated hydrolysis of PAF 16:0 and two 
lysoPAF species (16:0 and 18:0) were completed.  Representative Michaelis-Menten 
plots of initial velocity versus substrate concentrations for the hydrolysis of these 
substrates are shown in Figure 3.4B.  The kinetic parameters determined from this 
analysis are compiled in Table 3.2.  LysoPAF species had affinities that were 
approximately 3.5 to 5 times better (Km values lower) than PAF 16:0.  Likewise, the 
lysoPAF species had apparent affinities better by a factor of about two when compared to 
their corresponding LPC analogs.  Maximal reaction velocities were the highest for 
Table 3.2. Kinetic parameters for hydrolysis of glycerophospholipids 
















GPC 25 ± 1.0 0.1 ± 0.084 0.1 ± 0.01 0.4 ± 0.11 
LPC10:0 371 ± 6.0 0.7 ± 0.002 0.9 ± 0.02 0.2 ± 0.12 
LPC12:0 68 ± 1.0 0.6 ± 0.003 0.8 ± 0.03 1.2 ± 0.14 
LPC14:0 38 ± 0.7 2.0 ± 0.029 2.1 ± 0.02 5.5 ± 2.1 
LPC16:0 41 ± 0.3 1.3 ± 0.012 1.6 ± 0.01 4.0 ± 0.6 
LPC18:0 33 ± 0.7 1.3 ± 0.033 1.6 ± 0.04 4.8 ± 1.8 
PAF16:0 73 ± 1.0 1.8 ± 0.030 2.2 ± 0.03 3.0 ± 1.2 
LPAF16:0 21 ± 0.3 2.2 ± 0.180 2.7 ± 0.22 12 ± 5.8 




lysoPAF 16:0 and 18:0, as compared to both PAF and corresponding LPC analogues. 
NPP7 also exhibited a significantly higher catalytic efficiency for lysoPAF as shown by 
higher kcat/Km valuesin Table 3.2.   
 
3.4.6 Hydrolysis of synthetic compounds 
 Several synthetic substrates previously tested as substrates for either NPP2 (6, 13, 
14) or NPP6 (7) were selected and examined as substrates for NPP7ExFLAG. No 
NPP7ExFLAG catalytic activity was detected with FS-3 and para-nitrophenyl phenyl 
phosphate (pNPPP) (data not shown).  Likewise, only minimal activity was observed 
when bis-para-nitrophenylphosphate (bis-pNPP) or para-nitrophenylthymidine 
monophosphate (pNP-TMP) were used as substrates as evidenced by the very low para-





















































pNPPC 83 ± 5 2.0 ± 0.02 
2.4 ± 
0.022 
2.9 ± 0.8 
pNP-
TMP 
N/A: Minimal activity 
Bis-pNPP N/A: Minimal activity 
 
 
A        B 
 
Fig. 3.5.  Hydrolysis of synthetic nitrophenyl substrates by NPP7EXFLAG.  
Accumulation of the p-nitrophenolate anion from hydrolysis of 1mM pNPPC and 50mM 
bis-pNPP and pNP-TMP after 1 hour (A). The saturation curve for NPP7 hydrolysis of 






































































It is evident from Fig. 3.5A that para-nitrophenyl phosphocholine (pNPPC) is a 
much better substrate for NPP7ExFLAG than the other para-nitrophenyl containing 
compounds tested.  Here single concentrations of each substrate (1 mM pNPPC and 50 
mM of either bis-pNPP or pNP-TMP) are compared at a single assay time where the 
pNPPC hydrolysis rate was linear.  Due to low activity, no kinetic parameters could be 
determined for bis-pNPP or pNP-TMP.  In contrast, a Michaelis-Menten saturation curve 
for the hydrolysis of pNPPC is shown in Fig. 3.5(B) and Table 3.3 shows the calculated 
kinetic parameters.  pNPPC had an apparent Km value of 83 μM and Vmax of  0.2 µM∙sec
-
1
.  The Vmax, kcat and specificity constant values obtained for pNPPC were comparable to 
those obtained for the hydrolysis of PAF16:0 (Table 3.2). 
 The catalytic effiency for the hydrolysis of each tested substrate by NPP7 was 
compared by a plot of kcat/ Km shown in Figure 3.6. The graph shows the kcat/ Km values 
obtained for the hydrolysis of each substrate by NPP7 arranged based on the substrate 
groups tested. The enzyme exhibited greater catalytic efficiency against SM than SPC. 
Both lysoPAF species were hydrolyzed more efficiently than PAF16:0, the previously 
known substrate, but lysoPAF18:0 was the most efficiently utilized substrate by this 
enzyme. Statistical significance of the kcat/ Km values for lysoPAF18:0 and SM were 
calculated by the one way ANOVA software followed by the Bonferroni’s post test 
(KnowWare International, Inc, Denver, CO, USA) and gave a p value of <0.0001. 
Catalytic efficiency against various LPC chain lengths is also shown and the statistical 
analysis confirmed higher efficiency for the hydrolysis of LPC14:0 than LPC16:0. There 




















3.5  Discussion 
NPP isoforms have been reported to possess overlapping substrate specificity (6, 
15).  NPP2 is known to hydrolyze LPC and SPC but not PAF or SM (16).  Similarly, 
NPP6 has been shown to hydrolyze LPC, SPC, and lysoPAF but not PAF or SM (7).  
Here, we have shown that NPP7 is a more promiscuous lipid preferring isoform within 
the NPP family that is capable of hydrolyzing glycerolipids (LPC, PAF, lysoPAF) and 
 
Fig. 3.6. Comparison of NPP7 catalytic efficiency against all substrates.  The 
catalytic efficiency of NPP7 against previously known and newly identified 
substrates as depicted by the kcat/Km values is plotted on the y-axis. The statistical 
difference between the kcat/Km values for LPC14:0 and LPC16:0 was calculated 
using the one way ANOVA analysis followed by the Bonferroni post test analysis. 

































sphingolipids (SPC and SM), as well as para-nitrophenol containing substrates.  This 
makes NPP7 the only NPP isoform that has the ability to utilize substrates with more than 
one long hydrocarbon chain in their structures.  The results show that NPP7 has a 
preference for large lipid substrates.  NPP7ExFLAG showed very little activity toward 
GPC, the smallest natural substrate tested.  Likewise, NPP7ExFLAG failed to utilize bis-
pNPP, pNPPP, and pNP-TMP as substrates even in the mM concentration range.  In 
contrast, NPP7ExFLAG did utilize pNPPC as a substrate despite its small size.  The 
hydrolysis of pNPPC was similar to that of PAF 16:0 based on the panel of kinetic 
parameters determined. The calculated specificity constants (kcat/Km values) indicate that 
lysoPAF 18:0 was the best NPP7ExFLAG substrate, while lysoPAF 16:0 and SM 
followed closely.  
Further research is needed to identify the biological implications, if any, that these 
newly identified NPP7 substrates present.  SPC is a bioactive lipid known to activate a 
number of signaling cascades via G protein-coupled receptors although it is present in 
relatively low concentrations in human serum (17, 18). Synthetic and degradative 
pathways for SPC are not well understood but Xin et al. recently presented several 
theories (from SM, sphingosine and S1P) by which SPC accumulation could be possible 
(17).   SPC is an effective mitogen for various cell types and its levels are upregulated in 
several pathological conditions including Niemann-Pick disease and ovarian cancer (17, 
18). The hydrolysis of SPC by NPP7 generates sphingosine, an antiproliferative 
messenger. In contrast, the hydrolysis of SPC by NPP2 generates sphingosine-1-
phosphate, a regulator of migration (16). This finding again presents NPP7 as the 
anticancer NPP isoform as opposed to NPP2 which is a mediator of cancer development 
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and progression (19). Our finding has thus identified a possible SPC catabolic pathway 
for which the biological importance remains to be understood. 
LysoPAF is the main metabolite and precursor for the biosynthesis of PAF via the 
remodeling pathway under normal, as well as inflammatory conditions (20).  Recently 
lysoPAF was reported as a bioactive lipid with effects opposing those of PAF (21).  
NPP7ExFLAG hydrolyzed lysoPAF five times more effectively than PAF. The 
physiological levels and bioactivity of PAF are tightly controlled by inter conversion to 
lysoPAF by PAF acetylhydrolases (20).  Our findings suggest that NPP7 might play a 
role in the regulation of PAF by contributing to the clearance of its main metabolite and 
precursor but further studies are needed to analyze the effects of NPP7 on PAF/lysoPAF 
metabolism and bioactivity. 
Conversion of LPC16:0 to monoacylglycerol and phosphorylcholine by NPP7 has 
been known for some time but the influence of chain length on hydrolysis has not been 
explored in this type of kinetic analysis (22).  LPC16:0 has been predominantly used in 
previous work to characterize NPP7 (3, 5, 23, 24).  For the first time, this work has 
established that LPC14:0 is the preferred chain length for NPP7ExFLAG. For LPC chain 
lengths shorter than 12, affinity was decreased based on the Km values obtained.  
NPP7ExFLAG had the highest apparent affinity for GPC, the LPC substrate completely 
lacking an acyl chain.  However, GPC displayed the poorest conversion to products as 






.  NPP6 is the only other 
lysophospholipase C in the NPP family and was previously reported to hydrolyze 
LPC12:0 and GPC with the highest preference (7).   
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Para-nitrophenylphosphocholine (pNPPC) is a synthetic NPP7 substrate identified 
here for the first time.  Kinetic parameters for the NPP7ExFLAG mediated hydrolysis of 
pNPPC were similar to those obtained for PAF16:0.  NPP7 cleaves pNPPC with a 
lysophospholipase C activity, generating phosphocholine which can be monitored by 
fluorescence (Amplex Red assay) and para-nitrophenolate anion which can be monitored 
by absorbance at 405 nm. We have thus described a new assay method for monitoring 
NPP7 catalytic activity using this novel substrate. The use of radio-labeled lipid 
substrates has been the predominant method for monitoring NPP7 activity (4, 5, 8, 25) 
but this method is labor intensive, time consuming and expensive.  These new, alternative 
methods are an improvement over the previous method in both cost and ease of use.  The 
Amplex Red fluorogenic assay indirectly measures phosphocholine production via a 
series of exogenous enzymatic reactions to generate resorufin.  The absorbance assay 
based on pNPPC is inexpensive and is based on a direct NPP7 product (para-
nitrophenolate anion).  Both approaches provide for multiplex, multiwell plate analysis 
that allows for the type of complete kinetic analysis provided here for NPP7.   
Successful baculovirus expression of a truncated, biologically active 
NPP7ExFLAG construct has been described herein. NPP7 has been suggested to have 
five glycosylation sites and that mature enzyme is inactive without appropriate N-
glycosylation (5).  Insect cells are capable of expressing protein with post-translational 
modifications similar to mammalian cells (26). The molecular weight of the 
NPP7ExFLAG construct is approximately 48 kDa.  The expressed protein migrated to a 
position slightly above 50 kDa on SDS-PAGE and Western blots, indicating post-
translational modification occurs in Sf9 insect cells. 
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NPP7 has been reported to be inhibited by zinc and the inhibitory effects were 
prevented by 2 mM EDTA (2). Since this report, 2 mM EDTA has been a component of 
the NPP7/Alk-SMase assay buffer in all published NPP7 experiments (4, 24, 27). 
Contrary to previous reports, we establish here that NPP7/Alk-SMase catalytic activity is 
greatly hampered by EDTA. The current finding is not unusual considering NPP7 is a 
metalloenzyme which depends on the presence of divalent cations for its catalytic 
function (24).  The chelating abilities of EDTA may disrupt the metal enzyme 
interactions leading to reduced catalytic activity. Further investigations are underway to 
find out if this effect is dependent on EDTA concentration and/or time of exposure.  
 In conclusion, two cheaper, easier and multiplex methods for the assay of NPP7 
catalytic activity have been established as alternatives to the common use of radio-labeled 
substrates. Through these methods, we have extensively characterized and compared the 
kinetics of this enzyme against all its substrates. Several new substrates have been 
identified that may have biological implications but further research is needed to identify 
and characterize such effects. 
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COMPUTATIONAL IDENTIFICATION AND BIOCHEMICAL 
CHARACTERIZATION OF SUBSTRATE BINDING DETERMINANTS OF 
NUCLEOTIDE PYROPHOSPHATASE/ PHOSPHDIESTERASE-7 
 
4.1 Abstract 
 The nucleotide pyrophosphatase/phosphodiesterase (NPP) subfamily of alkaline 
phosphatases currently consists of seven human isoforms that are related in structure and 
function. They are all ectoenzymes that hydrolyze a wide variety of substrates to generate 
lipid messengers that mediate a range of physiological and pathological processes. NPP 
isoforms have been associated with conditions such as cancer, obesity, bone 
mineralization, allergy, growth, and development. Thus, they are attractive targets in drug 
discovery and development, however, they are not well understood in terms of their 
structure and function. NPP7 is a recent addition to this important family of enzymes. It 
hydrolyzes lipid substrates that lead to generation of both proliferative and 
antiproliferative messengers such as ceramide, sphingosine, and sphingosine 1-
phosphate. Like other NPPs, NPP7 recognizes a spectrum of substrates preferentially but 
it is not well understood what determines its well-defined substrate preferences. The aim 
of this work is to identify and characterize amino acid residues that contribute to substrate 





Nucleotide pyrophosphatase/phosphodiesterase-7 (NPP7) is a 60kDa membrane 
anchored ectoenzyme that hydrolyzes sphingomyelin (SM) (Nilsson 1969), platelet 
activating factor (PAF) (Wu et al. 2006), lysophosphatidylcholine (LPC) (Wu et al. 
2005), sphingosylphosphorylcholine (SPC) and lyso platelet activating factor (lyso PAF) 
(Wanjala I.W., A.L. Parrill and D.L. Baker, manuscript in preparation) to generate 
multiple signaling molecules. The enzyme has been implicated in pathological conditions 
such as cancer and atherosclerosis, as well as in  normal physiological processes such as 
cholesterol absorption and maturation of the intestinal tract (Wu et al. 2006).  However, 
NPP7 has not been well characterized in terms of its structure and function (Duan 2006). 
The nucleotide pyrophosphatase/phosphodiesterase (NPP) enzymes comprise a seven 
member subfamily of enzymes (Bollen et al. 2000). Individual NPP isoforms are 
classified as either pyrophosphatases or phosphodiesterases depending on the specific 
substrates they hydrolyze  (Kanda et al. 2008). NPP1, NPP2, and NPP3 are nucleotide 
pyrophosphatases that cleave inorganic phosphate from nucleotides and their derivatives 
(Clair et al. 1997; Gijsbers et al. 2003). In contrast, NPP2, NPP6, and NPP7 are 
phosphodiesterases that hydrolyze phosphodiester bonds in lipids and their derivatives, 
(Duan 2003; Sakagami et al. 2005; Umezu-Goto et al. 2002).  NPP4 and NPP5 are yet to 
be characterized in terms of substrate preferences.  NPP2 is the only member of the seven 
known NPP isoforms that possesses both pyrophosphatase and phosphodiesterase 
activities (Stefan et al. 2005).  As a phosphodiesterase, NPP2 exhibits lysophospholipase 
D (LPLD) (Umezu-Goto et al. 2002) activity which contrasts with the lysophospholipase 
C (LPLC) activities of NPP6 and NPP7. Besides these specific activities, no previous 
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experimental evidence is available to explain differences in substrate preference among 
the known lipid preferring NPP isoforms. (Bollen et al. 2000; Gijsbers et al. 2001) 
NPP7 has been previously shown to hydrolyze SM, LPC, and recently, we have 
also identified lyso platelet activating factor (lysoPAF), sphingosyl-phosphorylcholine 
(SPC), and para-nitrophenylphosphorylcholine (pNPPC) as additional NPP7 substrates 
(Wanjala, I.W., A.L.Parrill and D.L. Baker, manuscript in preparation).  Here we have 
used a combination of computational homology modeling, substrate docking, site-
directed mutagenesis and kinetic analysis of enzyme activity to examine the role of 
specific amino acid residues within the NPP7 active site in determining substrate 
recognition.  Homology modeling has not previously been applied to the analysis of 
NPP7 structure and function relationships and this work could open a new approach in 
the analysis of this important isoform. Our results suggest an overlapping binding pocket 
for all substrates examined and show that NPP7 activity against four of its substrates was 
differentially affected by specific site-directed mutations.  
 
4.3 Materials and Methods 
4.3.1 Generation of the NPP7 homology model 
 The bacterial Xac NPP structure (2gso) (Zalatan et al. 2006) was used as the 
template sequence and the human NPP7 nucleotide sequence (Genbank code AY20633) 
(Duan 2003) as the target for homology modeling.  Xac NPP is the most closely related 
analog of human NPP isoforms with a solved crystal structure, similar function, and 
relatively high sequence homology.  The Molecular Operating Environment (MOE 2008) 
software package (Chemical Computing Group, Montreal, Canada) was used for all 
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homology modeling and docking.  A database of eleven homology models was generated 
and each model was analyzed using a Ramachandran plot to identify those models with 
phi/psi angles outside the range represented in known crystal structures (outliers). Models 
were ranked based on the number of outliers and their proximity to the catalytic residue 
(threonine 75). The best models were those with fewer outliers that were located more 
than 10Å from the active residue. The selected model was then energy minimized using 
the Assisted Model Building and Energy Refinement (AMBER99) force field (Asada et 
al. 2002; Hornak et al. 2006; Wang et al. 2000) to generate the final model with which 
subsequent substrate docking was performed. 
 
4.3.2 Substrate docking 
Substrate docking was used to study interactions between NPP7 and its 
previously known substrates and their closely related analogs. pNPPC was directly 
docked into the active site as a whole molecule since it is small and has limited 
flexibility. The substrates LPC, PAF, and SM are highly flexible because of long fatty 
acyl chains in their structures. For this reason stepwise docking was done starting with 
the polar head groups of each substrate.  Wall restraints were also used to keep the 
substrate phosphate group in close proximity to the enzyme’s active residue, threonine 
75. The hydrophobic chains were then extended three carbon atoms at a time followed by 
energy minimization for the newly added atoms at each step.  The protein surface feature 
within MOE was used to visualize the various channels that could accommodate the 
substrates during binding. After extending the full chains, chain rotations were done 
followed by energy minimization to explore the best positions for each chain and thus the 
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minimum energy conformation for each substrate. The lowest energy conformation was 
then selected for each substrate and their interactions with the protein analyzed.  
 
4.3.3 Analysis of protein-substrate interactions  
 Protein residues within 4.5 Å of the substrate atoms were analyzed to determine 
the presence of non-covalent interactions.  Presence of such interactions was taken as 
evidence of higher affinity binding than complexes lacking such stabilizing interactions.  
All protein residues around the common substrate groups were identified and the 
distances separating them from the possible interaction points analyzed. The maximum 
interaction distance was set at 4.5 Å. All residues more than 4.5 Å away from their 
possible interaction points in all substrates were eliminated as noncovalent interaction 
strengths become weaker with increasing distance. The type of interaction formed by 
each residue was also analyzed. Stronger noncovalent interactions such as H-bonding, π-
stacking and cation-π interactions were considered more important than weaker 
interactions such as Van der Waal’s forces. Six mutation candidates were selected and the 
type of effect expected with a given type of single point mutation predicted. 
 
4.3.4 Site-directed mutagenesis of  NPP7 
The full length, human NPP7 insert (Genbank AY20633) contained within the 
mammalian expression vector pcDNA4/TO/myc his B, was kindly provided by Dr. Rui 
Dong-Duan (Lund University, Lund, Sweden).  The upstream cloning site was mutated 
from the Kpn1 to a BamH1 recognition sequence using the sense primer 5’-
GCGTTTAAACTTAAGCTTGGATCCGAAATGAGAG-3’ and antisense primer 5’-
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CTCTCATGCTTTCGGATCCAAGCTTAAGTTTAAACGC-3’ and the Quickchange 
site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) according to the 
manufacturer’s protocols.  The NPP7 insert was subcloned into the pcDNA3.1(+) 
mammalian expression vector using standard molecular biology approaches.  Next, a 
truncated, secreted version of NPP7 containing a FLAG affinity tag was generated by 
adding the sequence DYKDDDDK after T415 and before a stop codon using the sense 
primer 5’-CCCATGCTGCACACAGACTACAAGGACGACGATGACAAGTAG 
GAATCTGCTCTTCCG-3’ and antisense primer 5’-CGGAAGAGCAGATTCCTA 
CTTGTCATCGTCGTCCTTGTAGTCTGTGTGCAGCATGGG-3’ with the  
Quickchange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) according to 
the manufacturer’s protocols.  This truncated NPP7 construct lacked the C-terminal 
transmembrane anchor but has previously been shown to be functional and expressed as a 
secreted enzyme (Wu et al. 2005).  The complete affinity tagged fusion was termed 
NPP7ExFLAG.  All proposed site directed mutants were generated from this customized 
plasmid using standard PCR techniques and the multi site-directed mutagenesis kit 
(Stratagene, La Jolla, CA, USA) according to the manufacturer’s protocols. Table 4.1 






4.3.5 Mutant protein expression and normalization 
Wild type NPP7ExFLAG and all mutant proteins were expressed via transient 
transfection in human embryonic kidney cells (HEK293T).  HEK293T cells were grown 
in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% heat-inactivated fetal 
calf serum and 2 mM L-glutamine and 100 U/ml penicillin-streptomycin at 37 
o
C and 5% 
CO2 up to 80% confluence.  Transient transfections with wild type or mutant 
NPP7ExFLAG insert subcloned in the pcDNA3.1(+) mammalian expression vector were 
done using the Polyfect transfection reagent (Qiagen, Valencia, CA, USA) according to 
the manufacturer’s protocols.  Eight hours after transfection, the culture medium was 
changed to serum-free DMEM and cells were incubated for an additional 48 additional 
hours.  Conditioned media containing secreted NPP7 protein was collected and 
concentrated using 10,000 molecular weight cutoff (10K MWCO) filters (Millipore, 
Billerica, MA, USA) by centrifugation at 3073xg for 20 minutes. NPP7 proteins (wild 
type and mutants) present in concentrated conditioned medium (CCM) were stored at 4
o
C 
Table 4.1 Sense primers for NPP7ExFLAG mutants 










in NPP7 assay buffer, pH 8 without addition of adjuvants until functional activity was 
determined. 
Western blots were used to verify expression of NPP7ExFLAG and all its 
mutants.  The M2 Anti-FLAG antibody (Sigma-Aldrich, St. Louis, MO, USA) was 
utilized following standard protocols.  Following separation by SDS-PAGE on Tris-HCl- 
gradient gels (4-15%, Bio-Rad, Hercules, CA, USA) proteins were transferred onto 
polyvinylidene difluoride (PVDF) membrane (Bio-Rad, City, State, USA) by 
electroblotting at 100V in Tris/Glycine SDS buffer for 1 hour.  Nonspecific binding sites 
were blocked with 50 mM Tris buffered saline, 2.7 mM KCl, 138m M NaCl, 0.5% (v/v) 
Tween
®
20  (TBST) and 5% (w/v) non-fat dry milk (NFDM).  The membrane was then 
treated with M2 Anti-Flag antibody (Sigma-Aldrich, St. Louis, MO, USA) (1:2000 in 
TBST + 3% NFDM) and horseradish peroxidase conjugated goat anti-mouse IgG 
antibody (Sigma-Aldrich, St. Louis, MO, USA) (1:5000 in TBST + 3 % NFDM).  
Finally, SuperSignal Pico West chemiluminescent substrate (ThermoScientific, Rockford, 
IL, USA) allowed for chemiluminescence detection using a Luminary imaging system 
(Fotodyne, Hartland, WI, USA). 
All enzyme activity assays were performed with CCM that had been quantified at 
least twice by Western blot analysis. First, a scanning Western blot was run with varying 
dilutions of the CCM to assess the differences in the amounts of protein that could arise 
due to differing expression levels of mutants. Based on the results of the first Western 
blot, all samples were diluted to the same concentration and were verified by a second 
independent immunoblot. To quantify the amounts of protein expressed for each sample, 
a known concentration of the carboxy-terminal FLAG-BAP fusion protein (Sigma 
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Aldrich, St. Louis, MO, USA) was included on the second Western blot as a standard. All 
protein bands were normalized relative to the FLAG-BAP standard using the TotalLab 
software program in conjunction with the Luminary imager (Fotodyne, Hartland, WI, 
USA).  
 
4.3.6  Assay of NPP7 catalytic activity 
Fluorescence-based assay: Hydrolysis of LPC, PAF and SM by NPP7 was 
monitored using a modification of Invitrogen’s Amplex® Red phosphatidylcholine-
specific phospholipase C assay kit (Invitrogen, Carlsbad, CA, USA). NPP7 assay buffer 
was prepared as previously described (containing 50 mM tris-HCl, pH 8.0, 150 mM 
NaCl, and 10mM taurocholic acid (Nyberg et al. 1996). Unlike the previous work of 
Nyberg et al. we have determined that EDTA is an inhibitor of the hydrolytic activity of 
NPP7ExFLAG as one would expect for a metalloenzyme (Wanjala et al., manuscript in 
preparation).  Each well on a 96-well plate (half area, Corning, City State, USA) was 
loaded with a total of 60 µL consisting of 20 µL each of substrate, Amplex Red cocktail 
(10 μM Amplex Red reagent, 0.1 U/ml choline oxidase, 1 U/ml horseradish peroxidase, 4 
U/ml alkaline phosphatase) and normalized concentrations of enzyme diluted from CCM. 
The activity of wild type NPP7ExFLAG or mutants was determined by monitoring 
fluorescence (excitation 571 nm and emission 585 nm) every minute for two hours using 
a Synergy 2 multi-well plate reader (BioTek, Winooski, VT, USA). 
Absorbance-based activity assay: Hydrolysis of pNPPC as a function of 
NPP7ExFLAG activity was monitored via an absorbance assay based on the generation 
of para-nitrophenolate. This hydrolytic product has a maximum absorption at 405 nm. 
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Each well of a 96 well plate (half area, Corning, City State, USA) was loaded with a total 
of 60 µl consisting of NPP7 assay buffer, 400 µM of substrate and normalized amounts 
of enzyme from CCM.  Wild type NPP7ExFLAG or mutant activity was monitored by 
measuring absorbance at 405 nm every minute for two hours using a Synergy 2 multi-
well plate reader (BioTek, Winooski, VT, USA). 
 Dose response assays were run with varying substrate concentrations using the 
fluorescence-based (LPC, PAF, SM) or the absorbance-based assay (pNPPC). Relative 
fluorescence or absorbance units were converted to product concentrations using standard 
curves. For the fluorescence assay, varying concentrations of resorufin (the ultimate 
fluorescent product) were used to monitor the level of fluorescence in the presence of all 
other assay components with the exception of NPP7ExFLAG to generate a standard 
curve. For the absorbance assay, varying concentrations of para-nitrophenol were used in 
the presence of all other assay components with the exception of NPP7ExFLAG to obtain 
absorbance values at 405 nm for the standard curve. The trend line equations from these 
calibration curves were generated using Microsoft Excel (2007) and were used to convert 
all relative fluorescence and absorbance units to product concentrations.  Initial rates for 
all reactions were determined from the slopes of the linear ranges in the product versus 
time plots. Curve fitting on Michaelis-Menten initial rate versus substrate concentration 
plots was done using the KaleidaGraph 4.0 software package (Synergy software, 
Reading, PA, USA) data was fitted to the following equation y = m1 x m2x(1+ m2x) (Km 
= 1/m2 and Vmax = m2). The catalytic constant (kcat) was calculated by dividing Vmax by 




4.4.1 Generation of the NPP7 homology model 
 Fig. 4.1 shows the energy minimized NPP7 homology model obtained using the 
Xac crystal structure, PDB (Berman et al. 2000) entry 2gso (Zalatan et al. 2006), as 
template. The white circle highlights our designated binding pocket, an 8Å radius around 
the active site residue, threonine 75. The 8Å radius was selected because it was large 
enough to accommodate the polar headgroup of the large lipid substrates hydrolyzed by 
NPP7. In close proximity to the active residue are two divalent metal cations transferred 
directly from the Xac template.  Like all NPP isoforms, NPP7 requires divalent metal 
cations for its phosphodiesterase activity.The resulting NPP7 homology model displayed 
strong interactions between known metal ion coordinating residues (Asp 39, Asp 199, His 
203, Asp 246, His 247, His 353) and the two zinc ions (see Fig. 4.2).  All six of these 



















Fig. 4.1. NPP7 homology model. The homology model was generated in MOE 
using the general bacterial Xac NPP crystal structure (PDB entry 2GSO) as the 
modeling template and human NPP7 nucleotide sequence (Genbank Id AY20633) 
as the modeling target. The white circle highlights the proposed phosphate target 
area within the NPP7 active site, an 8Å radius around the active residue 
threonine75, which is shown as a space filling model. Residues shown in stick 
















4.4.2 Substrate docking 
Fig. 4.3 shows the results of stepwise docking for each of the three previously 
identified lysolipid substrates of NPP7.  All three choline groups are in close proximity 
and all phosphate groups docked within the same vicinity.  However, as one might 
reasonably expect due to the weaker, non-directional van der Waals interactions, the 
hydrophobic chains adopted different positions. Since there are no structural differences 
in the hydrophobic chains of the three substrates, we manually placed the chains for LPC 
 
Fig. 4.2. NPP7 homology model metal coordination sites. In close proximity to the 
active site residue threonine 75 are two divalent metal cations speculated to be present 
in NPP7 that result from homology modeling based on the Xac template.  Each metal 




and SM to follow the same shape as that of PAF. Energy minimizing these manually 
created poses gave conformations with drastically reduced energies and moved the 
common groups closer. Fig. 4.3 shows a superposition of these conformations which 
were used for analyzing interactions.   
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Fig. 4.3. Final docked conformations for LPC, PAF, SM and pNPPC in human 
NPP7. Minimized poses of all substrates have significant overlap within the active site. 
All common groups on different substrates are located within close proximity (A). The 
lipid substrates have a common basic structure whereas pNPPC is quite different (B) but 
the phosphocholine head groups for all docked in the same area.  




















4.4.3 Analysis of protein-substrate interactions  
 Table 4.2 summarizes the predictions made from the complexes of all docked 
substrates with the human NPP7 homology model.  The left column lists all residues 
within 4.5 Å of each substrate.  It is noteworthy that the same residues were identified for 
most substrates since their common functional groups were located within close 
proximity.  Only the second hydrophobic tail of SM gave unique interacting residues.  
Residues selected for mutation after analyzing the types and distances of predicted 
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4.4.4 Effect of mutations on the hydrolysis of LPC  
Fig. 4.4 shows the lowest energy docked conformation of LPC16:0 (shown in 
white ball and stick) in the NPP7 active site with mutated residues displayed as stick.  All 
mutants of residues colored green hydrolyzed LPC (16:0) with a higher overall kcat/Km 
than wild type NPP7ExFLAG enzyme.  Mutants of the residues colored red hydrolyzed 
LPC16:0 with a lower kcat/Km than did wild type NPP7ExFLAG.  All kinetic parameters 
obtained from activity assays are presented in Table 4.3. Wild type NPP7ExFLAG had an 
apparent Vmax of 2.5 μM/sec and a kcat value of 2.9 sec
-1
.  Three mutants (F80A, Y166A 
and E169A) displayed lower Vmax and kcat values than the wild type enzyme. These 
mutants also exhibited a lower affinity for LPC16:0 as seen from their Km values which 
are all higher than that of wild type enzyme.  Accordingly, their kcat/Km values are lower 
than the wild type enzyme. In the model, F80 and Y166 are located 4Å or less from the 
nonpolar palmitate chain of LPC.  Mutation to the smaller alanine residue would increase 
this contact distance and was predicted to have a detrimental effect on enzyme function 
(Table 4.2).  In contrast, E169 is located almost 6Å from the polar glycerol backbone of 
LPC, and mutation was not predicted to have a detrimental impact on hydrolysis of this 
substrate.  This apparent contradiction (especially with E169A mutation) between 
modeling predictions and experimental results might be mitigated if a water-bridged 
interaction occurs as water molecules were not included in these gas-phase docking 
studies.  One mutant (F275A) had no observable catalytic activity against LPC16:0.  This 
residue is located less than 4.5Å from the choline headgroup of LPC, and is oriented to 
make a cation-pi interaction.  Such an interaction is not possible in the alanine mutant, 
consistent with the loss of activity upon mutation. Three mutants (L107F, Y142A and 
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E169Q) exhibited higher Vmax and kcat values than the wild type enzyme. Interestingly, 
these three mutants also had higher Km values than the wild type enzyme. The 
combination of these values gives L107F a higher kcat/Km value while giving E169Q a 
lower kcat/Km value than wild type enzyme. In the model L107 is located 3.5 Å from the 
methyl of LPC choline group and 3.99 Å from the palmitate tail where it would 
potentially have hydrophobic interactions with both LPC regions. Mutation to a 
phenylanine introduces a phenyl ring with a favorable pi cloud to potentially form a 
cation-pi interaction with the positively charged LPC choline group and stronger 
hydrophobic interactions with the palmitate tail than the leucine. This led to the observed 
increase in catalytic activity of the L107F mutant as was computationally predicted. 
Y142 was selected as a control mutation site as it is located too far away from any of the 
substrates to have an effect on their hydrolysis. It is located 8.2 Å away from LPC 
palmitate tail (the closest interaction point). The unexpected results of an increase in Vmax 
with an alanine replacement may be due to an allosteric effect that led to better and faster 
product release. The increase in the Km value however, led to a kcat/Km value similar to 
that of the wild type enzyme as predicted by the model.  As noted previously, E169 is 
located about 6 Å away from the hydroxyl group on the polar glycerol backbone of LPC 
and its replacement with a glutamine led to a minimal effect in contrast to an alanine 
replacement. This result further indicates the possibility of a water-bridged interaction 
which was maintained with a glutamine replacement though the interaction would be 












Fig. 4.4.  LPC docked into the NPP7 homology model. LPC (16:0) is shown as 
white ball and stick.  Only mutated residues are shown (sticks) with mutation sites that 
increased kcat/Km in green and those that decreased kcat/Km in red. The distance (Å) of 
















4.4.5 Effect of mutations on hydrolysis of PAF 
Fig. 4.5 shows the lowest energy docked conformation of PAF16:0 (shown in 
gold ball and stick) in the NPP7 active site with mutated residues displayed as stick.  All 
mutants of residues shown in green hydrolyzed LPC (16:0) with a higher overall kcat/Km 
than wild type NPP7ExFLAG enzyme.  Mutants of the residues shown in red hydrolyzed 
LPC16:0 at a lower kcat/Km than did NPP7ExFLAG.  All kinetic parameters obtained 
from activity assays are presented in Table 4.4. Wild type NPP7ExFLAG had an apparent 
Vmax of 1.3 μM/sec and a kcat value of 1.6 sec
-1
.  Three mutants (F80A, Y166A and 
E169A) exhibited slightly lower Vmax and kcat values and higher Km values than the wild 
type enzyme. Accordingly, these substrates also had lower specificities for the substrate 
as seen from their kcat/Km values. In the model, F80 and Y166 are both less than 4 Å from 
Table 4.3 Kinetic parameters for hydrolysis of LPC 16:0. 
Enzyme Km (μM) 
Vmax (μM/sec)  (x 10
-2) kcat(sec
-1) kcat/Km (M
-1sec-1) (x 104) 
L107F 61 ± 2.8 3.5 ± 0.03 4.2 ± 0.03 6.8 ± 1.6 
Y142A 69 ± 0.9 3.0 ± 0.01 3.6 ± 0.01 5.2 ± 0.05 
Wild type 57 ± 0.7 2.5 ± 0.01 2.9 ± 0.01 5.1 ± 0.1 
E169Q 88 ± 6.8 3.3 ± 0.02 3.8 ± 0.03 4.3 ± 0.4 
E169A 100 ± 15 1.0 ± 0.04 1.2 ± 0.05 1.2 ± 0.2 
F80A 120 ± 3.0 0.7 ± 0.01 1.4 ± 0.01 1.2 ± 0.3 
Y166A 100 ± 5.0 0.9 ± 0.03 1.1 ± 0.03 1.0 ± 0.2 




the non polar palmitate chain of PAF16:0.  As for LPC, mutation to the smaller alanine 
residue would increase these contact distances and was predicted to have a detrimental 
effect on enzyme function (Table 4.2).  Unlike LPC, E169 is located 3.15 Å from the 
acetyl group of PAF, and mutation was not predicted to have a detrimental impact on 
hydrolysis of this substrate due to a possible unfavorable interaction between the 
hydrophobic methyl group (on PAF acetyl group) and the polar side chain of E169. The 
possibility of a water-bridged interaction between E169 and the polar oxygen atoms on 
PAF could again mitigate this apparent contradiction between modeling predictions and 
experimental results.  One mutant (F275A) had no observable catalytic activity against 
PAF16:0. As for LPC, this residue is located less than 4.5 Å from the choline head group 
of PAF16:0, and is oriented to make a cation-pi interaction.  Such an interaction is not 
possible in the alanine mutant, consistent with the loss of activity upon mutation. Three 
mutants (L107F, Y142A and E169Q) exhibited higher Vmax and kcat values than the wild 
type enzyme. L107F and E169Q also had higher Km values but L107F also had a much 
higher Vmax (thus kcat) value that led to a kcat/Km value above that of the wild type 
enzyme. In contrast E169Q had a higher Km value that led to a lower specificity constant 
than that of wild type enzyme. Y142A had a lower Km value than that of wild type 
enzyme and this combined with the higher kcat value led to a kcat/Km value higher than 
that of wild type enzyme. The L107F, Y142A and E169Q effects can be similarly 








Fig. 4.5. PAF docked into the NPP7 active site. PAF (16:0) is shown as gold ball and 
stick.  Only mutated residues are shown (sticks) with those that increased kcat/Km in 
green and those that decreased kcat/Km in red. The distance (Å) of each residue from the 












4.4.6 Effect of mutations on hydrolysis of SM 
 Fig. 4.6 shows the lowest energy docked conformation of SM (shown in blue ball 
and stick) in the NPP7 active site with mutated residues displayed as stick.  Mutants of 
residues colored green hydrolyzed SM with a higher overall kcat/Km than wild type 
NPP7ExFLAG.  Mutants of residues colored red hydrolyzed SM at a lower kcat/Km than 
did NPP7ExFLAG.  Residue E169 is colored partially red and partially green because 
two mutations were made and each had an opposite effect compared to the wild type 
enzyme. All kinetic parameters obtained from activity assays are presented in Table 4.5. 
Wild type NPP7ExFLAG had an apparent Vmax of 3.0 μM/sec and a kcat value of 3.7 sec
-
1
.  Four mutants (F80A, Y166A, E169A and F275A) exhibited lower Vmax and kcat values 
than the wild type enzyme. Interestingly, all these mutants exhibited lower Km (14 μM for 
Table 4.4 Kinetic parameters for hydrolysis of PAF16:0. 




-1sec-1) (x 104) 
Y142A 75 ± 2 2.0 ± 0.03 2.5 ± 0.04 3.3 ± 0.6 
L107F 94 ± 3 2.4 ± 0.3 2.9 ± 0.3 3.1 ± 0.2 
Wild type 82 ± 2 1.3 ± 0.02 1.6 ± 0.02 2.0 ± 0.8 
E169Q 130 ± 8 1.9 ± 0.1 2.3 ± 0.2 1.7 ± 0.2 
F80A 120 ± 3 1.2 ± 0.03 1.4 ± 0.03 1.2 ± 0.4 
E169A 95 ± 6 0.8 ± 0.02 0.80 ± 0.02 1.0 ± 0.2 
Y166A 200 ± 10 0.7 ± 0.02 0.80 ± 0.04 0.4 ± 0.2 




F80A, 17 μM for E169A and 12 μM for F275A and Y166A) values meaning they bound 
SM better than the wild type enzyme (23 μM). However, E169A and F275A had lower 
kcat/Km values due to their much more reduced kcat values. These two mutants bound SM 
more tightly than wild type enzyme but were the least efficient in converting the substrate 
to product as seen from the drastically reduced kcat/Km values. F80A had a kcat/Km value 
slightly higher than that of wild type enzyme. In the model, F80 and Y166 are located 4 
Å or less from the non polar sphingoid chain of SM.  Mutation to the smaller alanine 
residue would increase this contact distance and was predicted to have a detrimental 
effect on enzyme function (Table 4.2).  F275 is about 4 Å away from the choline group of 
SM and its mutation to an alanine was predicted to have detrimental effects due to 
elimination of a cation-pi interaction. The results obtained match this prediction but the 
low Km value was unexpected and indicates that the change led to better binding affinity 
for SM but without generation of much product. E169 was closer to the sphingoid chain 
(second hydrophobic chain) chain of SM and evidently has a hydrogen bond with a 
hydroxyl group on the substrate. Replacement of the glutamate with an alanine 
eliminated this hydrogen bond and led to the observed reduction in hydrolysis. Three 
other mutants (Y142A, Y166A and E169Q) exhibited Vmax and kcat values that were 
essentially similar to the wild type enzyme. Of these, Y142A had a Km value twice that of 
wild type enzyme meaning it had half the binding affinity compared to that of wild type 
enzyme for SM while Y166A and E169Q had reduced Km values and accordingly 






) compared to that 






).  In the model, L107 is less than 4.5 Å from the 
interaction sites with SM (choline head group and sphingoid chain). Its change to the 
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larger, more hydrophobic phenylanine improved the van der Waal’s interactions with the 
palmitate chain and introduced a cation-pi interaction with the choline head group leading 
to the observed increase in the Vmax and kcat values for SM hydrolysis by L107F. 
However, the higher Km and kcat/Km values indicate poorer binding and lower specificity 
for the substrate and this is probably because the larger phenylanine residue reduced the 
space needed for the bulky SM substrate. In the model, Both Y166 and E169 are within 
less than 4 Å of the hydrophobic chains of SM. They both had drastically reduced Km 
values that led to higher kcat/Km values. Changing Y166 to alanine may have allowed SM 
to better fit into the binding pocket and hence the reduced Km value. Replacing E169 with 
a glutamine replaced a negatively charged side chain with an uncharged amide side chain 
close to the hydrophobic portion of the substrate leading to better binding because the 































Fig. 4.6. SM docked into the NPP7 active site. SM is shown as blue ball and 
stick. All mutation points are shown with those that increased kcat/Km in green and 
those that decreased kcat/Km in red. The distance (Å) of each residue from the 
















4.4.7 Effect of mutations on hydrolysis of pNPPC 
 Fig. 4.10 shows the lowest energy docked conformation of pNPPC (shown in 
yellow ball and stick) in the NPP7 active site with mutated residues displayed as stick.  
Mutants of residues colored green hydrolyzed pNPPC with a higher kcat/Km than the wild 
type NPP7ExFLAG enzyme.  Mutants of residues colored red hydrolyzed pNPPC at a 
lower kcat/Km than did NPP7ExFLAG.  Residue E169 is left in natural element colors 
because two mutations were made and each had an opposite effect compared to the wild 
type enzyme. All kinetic parameters obtained from activity assays are presented in Table 
4.6. Wild type NPP7ExFLAG had an apparent Vmax of 1.1 μM/sec and a kcat value of 1.4 
sec
-1
.  Four mutants (F80A, Y166A, E169A and F275A) exhibited lower Vmax and kcat 
values, as well as higher Km values, and accordingly had lower specificities than the wild 
Table 4.5 Kinetic parameters for hydrolysis of SM. 
Enzyme 
Km (μM) Vmax (μM/sec)  (x 10
-2) kcat (sec
-1) kcat/Km (M
-1sec-1) (x 104) 
E169Q 15 ± 5 3.2 ± 0.08 3.8 ± 0.1 25.0 ± 6.0 
Y166A 12 ± 0.4 2.6 ± 0.01 3.1 ± 0.2 25.8 ± 5.0 
F80A 14 ± 6 2.2 ± 0.3 2.6 ± 0.3 18.6 ± 5.0 
Wild type 23 ± 3 3.0 ± 0.1 3.7 ± 0.2 16.5 ±  4.0 
E169A 17 ± 2 1.8 ± 0.1 2.2 ± 0.2 11.6 ± 2.0 
L107F 37 ± 3 3.5 ± 0.1 4.2 ± 0.1 11.4 ± 4.0 
Y142A 47 ± 7 3.1 ± 0.2 3.7 ± 0.2 7.9 ± 3.0 




type enzyme. From the model, F80 and Y166 are too far away from the substrate and 
were predicted not to have effects when mutated to alanine. The contradictory effects 
may indicate that their mutations led to allosteric effects that affected recognition of this 
substrate. It is also possible that this model did not correctly depict pNPPC since we 
emphasized mostly the three natural substrates that were known at the time the model 
was generated. Two mutants (L107F and Y142A) exhibited Vmax and kcat values above 
those obtained with the wild type enzyme. L107F also had a slightly lower Km value than 
that of wild type enzyme and thus a higher kcat/Km value for pNPPC. Y142A on the other 
hand had a higher Km value than wild type enzyme but similar specificity constant due to 
an improved kcat value. In the model, L107F less than 4.5 Å away from the choline 
headgroup of pNPPC and thus its mutation to a phenylanine introduced a cation-pi 
interaction yielding the expected effects. Y142A was too far away and its effects here, as 
with the other substrates, were minimal. One mutant (E169Q) had Vmax and kcat values 
similar to those obtained with wild type enzyme and as seen from the model, E169 is 
located about 6 Å away from the substrate and its mutation was accordingly predicted to 
























Fig. 4.7. pNPPC docked into the NPP7 active site. pNPPC is shown as yellow 
ball and stick.  Only mutated residues are shown (sticks) with those that increased 
kcat/Km in green and those that decreased kcat/Km in red. The distance (Å) of each 
residue from the closest interaction point on the substrate is also shown. 
 
Red – reduced activity











4.5 Discussion  
 NPP enzymes have been reported to possess well-defined substrate specificity but 
it is not known what determines this property (Stefan et al., 2005). Separate substrate 
recognition surveys have been performed for NPP2 (Clair et al. 2003) and NPP6 
(Sakagami et al. 2005) and established the ability of these two phosphodiesterases to 
discriminate between substrates with very small structural variations. For instance NPP2 
hydrolyzes LPC and SPC but not PAF. Likewise, NPP6 readily recognizes and 
hydrolyzes LPC and lysoPAF but not PAF. We recently conducted a detailed survey of 
substrate recognition by NPP7 and identified lysoPAF and SPC as endogenous 
phospholipid substrates in addition to the previously known LPC, PAF and SM. These 
findings made NPP7 the only NPP isoform that has the ability to hydrolyze lipids with 
Table 4.6 Kinetic parameters for hydrolysis of pNPPC. 
Enzyme 
Km (μM) Vmax (μM/sec)  (x 10
-2) kcat (sec
-1) kcat/Km (sec
-1 M-1) (x 104) 
L107F 
310 ± 5.0 1.4 ± 0.05 1.7 ± 0.1 0.60 ± 0.02 
Wild type 
360 ± 8.0 1.1 ± 0.01 1.4 ± 0.1 0.40 ± 0.03 
Y142A 
400 ± 4.0 1.4 ±  0.01 1.7 ± 0.1 0.40 ± 0.02 
F80A 
450 ± 10.0 0.63 ± 0.04 0.8 ± 0.1 0.20 ± 0.1 
E169A 
170 ± 30.0 0.42 ± 0.03 0.5 ± 0.03 0.30 ± 0.02 
E169Q 
440 ± 5.0 1.2 ± 0.02 1.4  ± 0.1 0.30 ± 0.02 
Y166A 
820 ± 20.0 0.62 ± 0.03 0.7 ± 0.04 0.09 ± 0.01 
F275A 




one or two long hydrophobic tails. In this study, we have used molecular modeling and 
experimental mutagenesis to identify and characterize amino acid residues that determine 
NPP7 substrate recognition. We have further used experimental mutagenesis to validate 
these computational results and characterize the role of each identified residue in 
determining NPP7 substrate recognition and preferences.  
The use of homology modeling to study NPP7 is a challenging task and has not 
been previously reported likely because none of the NPP isoforms have a publicly 
available solved crystal structure. The only crystal structure currently available is the 
bacterial Xac NPP (Zalatan et al., 2005) structure which was found to share 34% identity 
with human NPP7. Experimental validation of the modeling predictions was therefore an 
important aspect of this study. Results for the hydrolysis of LPC16:0 show a match with 
computational predictions for all predicted amino acids with the exception of E169A 
which led to an unexpected decrease in kcat/Km.  However, this discrepancy can be 
logically mitigated if there exists a water-bridged interaction between the residue E169 
and the polar glycerol backbone of LPC16:0 since water molecules were not including in 
our modeling system. This fact is further reinforced by the E169Q mutation which led to 
only a small decrease in kcat/Km value. The glutamine replacement in this case retained 
the ability to hydrogen bond (water-bridged) with the glycerol backbone of LPC16:0 
although to a lesser extent than a glutamate would. The Y142A mutant had a kcat/Km 
value that was essentially the same as that of the wild type enzyme. This was 
computationally expected as this residue was approximately 8 Å away from the possible 
interaction point with LPC. The modeling predictions with residues F80A, Y166A, 
E169A and F275A having a reduction in catalytic function (increased Km, reduced Vmax, 
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kcat and kcat/Km) and L107F having an overall increase in function (although with a slight 
increase in Km value) were experimentally observed.  All computational predictions for 
the hydrolysis of PAF16:0 were matched by experimental results with all mutants except 
for Y142A. The contradictory results in the case of Y142A with PAF16:0 could be due to 
an allosteric effect that led to faster product generation even with lower substrate affinity 
than the wild type enzyme. With both substrates, there was an increase in the Km value 
with mutations that generally led to improved Vmax and kcat values probably because of 
minimally altered folding of the protein. Ultimately, the experimental results for 
hydrolysis of LPC16:0 and PAF16:0 show that the homology model and the predictions 
made from it are valid and we can therefore conclude that LPC16:0 and PAF16:0 occupy 
a common binding pocket within the active site of NPP7.  
The effects on the hydrolysis of SM were significantly different compared to 
LPC16:0 and PAF16:0. Y166A, one of the three mutations that had detrimental effects on 
hydrolysis of LPC16:0 and PAF16:0 had a significant enhancement in the hydrolysis of 
SM. This contradiction in computational predictions and experimental results is likely 
due to the bulky size of SM which which necessarily requires more space to fit within the 
NPP7 active site. This explains the positive effect observed when the larger tyrosine 166 
residue is replaced with a much smaller alanine residue. L107F, which led to an increase 
in hydrolysis of LPC16:0 and PAF16:0 as was predicted by modeling, only slightly 
increased the Vmax and kcat against SM but also increased the Km value, leading to lower 
specificity for this substrate. This also can be explained if the bulky size of SM is 
considered. The smaller L107 residue was replaced by a much larger phenylalanine that 
could be sterically unfavorable for SM binding. This indicates that SM may not bind in 
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exactly the same binding pocket as LPC16:0 and PAF16:0 or that the residues selected do 
not interact with SM as they do with LPC and PAF. Another interesting mutation site 
with regard to SM hydrolysis was E169. E169A led to a significant reduction in all 
kinetic parameters except Km whereas E169Q led to a significant decrease in Km and an 
increase in Vmax, kcat, and kcat/Km values leading to an overall better catalytic function of 
E169Q than the wild type. Effects observed for both of these mutations clearly indicate 
the importance of this site in the recognition of SM by NPP7. The drastic reduction in 
performance with the E169A mutation is evidence of elimination of the important 
hydrogen bond between E169 and SM (Figure 4.6). The significant improvement in 
performance with the E169Q is evidence not only of the H-bond between glutamine and 
SM but also of the improved electrostatic interactions when a negatively charged side 
chain (E169) was replaced with a neutral residue (Q169). E169 mutants had the largest 
effect on hydrolysis of SM compared to the other mutants made and since SM is 
currently the only substrate with two long hydrophobic chains, we can conclude that the 
second chain of SM plays an essential role in its recognition by NPP7. The reversal in 
effects on hydrolysis of SM with majority of the mutants in comparison to hydrolysis of 
the other substrates is a strong indication that the manual manipulation of the palmitate 
chain led to a biased model of SM and more refinement needs to be done in the future to 
identify the exact binding pocket for this substrate. 
Para-nitrophenylphosphorylcholine (pNPPC) is a synthetic compound recently 
identified as a substrate for NPP7. It is much smaller in size than the three known lipid 
substrates with much lower degree of flexibility. The mutants made were mainly based 
on the docking results of the three lipid substrates but experiments run with pNPPC 
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showed that mostof computational predictions were matched by experimental results. 
This indicates that pNPPC, PAF and LPC, all bind in a common binding pocket within 
the NPP7 active site. However the model for pNPPC needs refinement as some the 
mutations had unexpected effects although they matched those of PAF and LPC. In its 
current conformation (Fig. 4.7), residues F80 and Y166 are located more than 10Å away 
from pNPPC but experimentally had a significant reduction in overall performance of the 
enzyme. This indicates that pNPPC binds in the same pocket as LPC and PAF but may 
do so with a different conformation than that shown in the model to account for the 
mutation effects.  
To identify substrate-binding determinants, the magnitude and/or direction of 
effect of each mutation was compared for the different substrates. Fig. 4.8 summarizes 
the kcat/ Km values for each mutant normalized to that of wild type against the same 
substrate. Out of all the mutations made, only F275A led to loss of activity against some 
of the substrates (LPC and PAF) and retained minimal activity against SM and pNPPC. 
This residue was predicted to make a cation/pi interaction with the choline groups of all 
substrates tested. It would have been interesting to investigate its effects on a substrate 
without a choline head group but unfortunately, all currently known substrates for NPP7 
have this common functional group. Y166A led to large reduction in recognition of LPC, 
PAF and pNPPC (reduced kcat/Km values) but increased SM recognition (increased 
kcat/Km value).  Since SM is bulkier than all the other three substrates, the replacement of 
Y166 with an alanine may have allowed more space to accommodate substrate in the 
binding pocket. These data show that Y166 is important in LPC, PAF and pNPPC 
recognition but not in the recognition of SM by NPP7.  Conversely, L107F led to a 
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significant increase in kcat /Km of PAF, LPC and pNPPC but reduced the kcat/Km for SM 
indicating that L107 is important for SM recognition but probably not as essential for the 













To analyze substrate specifying determinants for NPP7 as opposed to other NPP 
isoforms, an alignment of the amino acid sequences of all NPP enzymes was done and 
the residues in other NPP isoforms that aligned with the NPP7 mutation sites were 
identified as shown in Table 4.5.  An interesting observation is that three (F80, L107, and 
Y142,) of the six NPP7 mutation sites identified by computational modeling were  
 
Fig. 4.8. Relative kcat/Km values of all mutants for hydrolysis of all substrates, 
LPC (white bars), PAF16:0 (light grey bars), pNPPC (dark grey bars and SM 
(black bars). The relative kcat/Km values were obtained by dividing the Km value of 


































conserved in all other NPPs but were different in NPP7.  Additionally, one residue 
(E169) was a conserved arginine in all NPPs except NPP6 which had a phenylanine. 
Only one mutation (L107F) was changed to the residue in the other NPP isoforms and 
experimental results indicate its importance in SM recognition. NPP7 is the only NPP 
enzyme that hydrolyzes SM. From Table 4.5, we can conclude that L107 and E169 
provide for the specificity for SM by NPP7. In place of E169, NPP6 has a phenylalanine 
while the other five isoforms contain an arginine. Both phenylalanine and arginine are 
much bulkier than the glutamate in NPP7 which further accounts for the ability of NPP7 
to bind this larger substrate that is not recognized by NPP2 and NPP6.  Mutation of the 
other five NPP7 mutation sites to those aligned in other isoforms may shed more light on 
Table 4.7 NPP7 mutation sites aligned with all human NPP isoforms  
Isoform Active site Mutation site 
NPP7 T75 F80A L107F Y142A Y166A E169A/Q F275A 
NPP6 S71 Y76 F103 W139 D163 F166 Q265 
NPP5 T72 Y77 F104 W139 F163 R166 T262 
NPP4 T70 Y75 F102 W136 F160 R163 T261 
NPP3 T205 Y210 F237 W271 F295 R298 F396 
NPP2 T210 Y215 F242 W276 H282 R285 I435 




specificity among these enzymes. It would be interesting to see if F166E and R285E can 
lead to SM recognition by NPP6 and NPP2, respectively. 
In conclusion, this work is the first of its kind where homology modeling has been 
used to study structure-activity relationships in the NPP7. Although the template used 
had only 34% amino acid identity with the NPP7 target sequence, validation results have 
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THE ROLE OF DIVALENT METAL CATIONS IN NPP7 
 
5.1 Introduction 
Like all known NPP isoforms, NPP7 is presumed to be a metalloenzyme that 
depends on the presence of specific divalent metal cations for its catalytic function (1, 2). 
The catalytic cycle for the seven known NPP enzymes has been described based on that 
of the related and well studied phospho- and sulfo-coordinating enzymes which includes 
the alkaline phosphatase superfamily (3, 4).  Here we describe the use of circular 
dichroism spectroscopy and enzyme activity determination to investigate whether the 
active site divalent metal cations play solely functional or a combined structural and 
functional role in NPP7. Our results show that these active site divalent metal cations 
play only a functional role in this isoform.  These experiments were performed in parallel 
with the NPP2 and NPP6 isoforms as part of a comparative survey.  Similar results were 
obtained for all three isoforms studied, thus similar conclusions were reached concerning 
the functional role of divalent cations in these related isoforms. Here the focus will be on 
studies of NPP7 with discussion of those pertaining to NPP2 and NPP6 when appropriate.  
The comparative survey, in its entirety, is a manuscript co-authored by Truc Chi T. Pham, 
Irene W. Wanjala, Angela, L. Howard, Abby L. Parill, and Daniel L. Baker which is to be 
submitted to the Biochemical Journal. 
 Previously published data suggested that the catalytic activity of NPP7 was 
inhibited by the presence of 0.25 mM zinc cations and that this inhibitory effect was 
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prevented by the addition of 2 mM ethylene diaminetetraacetic acid (EDTA) (1). These 
findings are hard to rationalize based on the fact that NPP7, like all NPP isoforms, is a 
metalloenzyme that requires divalent metal cations for catalytic function (2-5). As part of 
a comparative analysis to determine the role (structural and/ or functional) of divalent 
metal cations in the three known lysophospholipid preferring NPP isoforms, NPP2, 
NPP6, and NPP7, experiments detailing the effect of divalent metal ions on the structure 
and function of NPP7 were performed. Results indicated that all three NPP isoforms are 
inhibited by EDTA at an enzyme:EDTA molar ratio greator or equal to 1:120 and that the 
addition of divalent metal cations (including cobalt, nickel and zinc for NPP7) to these 
inactivated enzymes can restore most of the lost activity. We also show that neither 
EDTA (which inhibited the enzyme) nor the divalent metal cations (which restored 
enzyme activity) altered the secondary structure of the enzyme. 
 
5.2 Experimental Design 
5.2.1 EDTA treatment 
 Human NPP7ExFLAG protein was expressed and purified using the baculovirus-
Sf9 insect cell system described in Chapter 2, sections 2.3.2-2.3.4.   Affinity purified 
protein was used with stock solutions of varying ETDA concentrations to generate 
samples with increasing molar ratios of NPP7 protein to chelator (NPP7:EDTA ratios of  
1:0, 1:1, 1:2, 1:4, 1:8, 1:20, and 1:120). To prepare these samples, equal volumes (5 μL) 
of NPP7ExFLAG (8 μM) was mixed with EDTA stocks in CD buffer (10 mM Tris, 10 
mM NaCl, pH 7.4) at 0 μM, 8 μM, 16 μM, 32 μM, 64 μM, 160 μM and 720 μM. 
Duplicate samples were made for each EDTA treatment. One set of the samples was 
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immediately incubated at 4
o
C for 30 minutes while the other set was incubated for 16 
hours.  Following the incubation period, the catalytic activity of NPP7 was examined 
using para-nitrophenylphosphocholine (pNPPC, Sigma-Aldrich, St. Louis, MO, USA) as 
the substrate.  NPP7ExFLAG:EDTA samples were diluted to an enzyme concentration of 
30 nM in NPP7 assay buffer (50 mM Tris-HCl, 150 mM NaCl, 10mM sodium 
taurocholate, pH 7.4) before addition onto the plate. Each reaction well contained a total 
of 60 µL consisting of 20 µL each of 30 nM enzyme sample, 500 µM pNPPC and NPP7 
assay buffer.  In this activity assay, the absorbance of the para-nitrophenolate anion 
product generated by the lysophospholipase C activity of NPP7 was monitored at 405 nm 
every minute for a period of one hour using a Synergy-2 plate reader (BioTek, Winooski, 
VT, USA). The relative responses of all enzyme/EDTA samples were determined at the 
60
th
 minute of the assay where responses were linear.  All data were normalized to the 
zero EDTA control. 
 
5.2.2 Metal ion restoration 
 Samples containing NPP7ExFLAG and EDTA in a 1:120 molar ratio were 
prepared by adding 10 μL of purified NPP7ExFLAG (6 μM) to 10 μL of EDTA solution 
(720 μM).  This mixture was incubated for 16 hours at 4 
o
C and diluted 1:100 with NPP7 
assay buffer (50 mM tris-HCl, 150 mM NaCl, and 10mM sodium taurocholate, pH 7.4).  
These working stocks contained 30 nM NPP7ExFLAG and 3.6 µM EDTA (maintaining 

















) were prepared in NPP7 assay buffer.  Equal volumes of the 
enzyme:EDTA working stock were then combined with each metal chloride solution 
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resulting in a solution with final enzyme:EDTA:metal molar ratios of 1:120:1 x 10
6
 thus 
constituting saturating amounts of EDTA compared to enzyme and metal cation 
compared to EDTA.  These mixtures were incubated at 4 
o
C for either 30 minutes or 16 
hours. At the end of the incubation periods, the catalytic activity of the enzyme was 
monitored as described using para-nitrophenylphosphocholine as substrate. 
 
5.2.3 Structural studies using CD spectroscopy 
To determine the effect of metal ion removal by EDTA treatment and of the 
restoration of divalent metals on the secondary structure of NPP7ExFLAG, the following 
sets of samples were prepared.  First, NPP7ExFLAG (8 µM, 10 µL) was diluted with 10 
µL of CD buffer (control sample).  Second, additional samples were generated by mixing 
NPP7ExFLAG (8 µM, 10 µL) with 10 µL of 960 µM EDTA in CD buffer, pH 7.4 (pH 
7.0 for the Zn sample).  All samples were incubated for 16 hours at 4°C.  Addition of 280  
µL of CD buffer to the control and one of the ETDA treated samples made up the 
volumes to 300 µL that were analyzed for secondary structural compositions on a model 
410  CD spectrophotometer (Aviv biomedical Inc., Lakewood, NJ,  USA).  Wavelength 
scans were done at 25 °C from 190 to 260 nm in a 1 mm cuvet (zinc samples were 
studied in 10 mm cuvettes).  The 300 µL samples used for the wavelength scan were 
diluted to 3 mL using CD buffer followed by CD thermal scans at 222 nm from 20 to 100 
°C using a 10 mm cuvet.  Metal treatment samples were prepared by diluting with 200 µL 
of 200 mM stocks of CaCl2, CoCl2, or NiCl2 (instead of CD buffer used for controls) and 
were incubated for either 30 minutes or 16 hours at 4°C.  Wavelength and thermal scans 




formed insoluble Zn(OH)2  at pH values higher than 7.0, all CD experiments in the 
presence of Zn
2+
 were performed at pH 7.0.  EDTA treated working stocks were prepared 
as described previously with the exception that the CD buffer was pH 7.0 rather than pH 
7.4 for the zinc-treated samples.   
 
5.3 Results 
5.3.1 EDTA treatment 
Fig. 5.1 shows the effect of EDTA treatment on the activity of recombinant, 
purified NPP7ExFLAG.  Treatment of NPP7 with EDTA up to a 120 fold excess (30 
minute incubation) showed ≥ 90% of the untreated enzyme activity using pNPPC as 
substrate. Similarly, 16 hour incubation with molar ratios of EDTA lower than 1:20 had 
little impact on enzyme activity.  In contrast, 16 hours of exposure to EDTA at a 1:20 
molar ratio decreased activity by approximately 30%, whereas EDTA treatment at a 
1:120 molar ratio led to a reduction in activity of approximately 90% in NPP7ExFLAG 





5.3.2 Metal ion restoration 
 Sixteen hours of treatment with EDTA at a 1:120 molar ratio significantly 
inhibited NPP7ExFLAG activity.  We speculate this was due to the loss of one or more of 
the required, active site divalent metals.  To address whether this effect on enzyme 
activity was reversible or not, divalent metals were added back to EDTA-treated 
NPP7ExFLAG protein and enzymatic function was determined using pNPPC as 








) out of the seven divalent 
metals tested restored activity of EDTA-treated NPP7ExFLAG above 20% within 30 
 
Fig. 5.1.  The effect of EDTA on the catalytic activity of NPP7ExFLAG.  
NPP7ExFLAG was treated with EDTA at various molar ratios of 1:0, 1:1, 1:2, 1:4, 
1:8, 1:20, and 1:120 at 4
o
C for 30 minutes (white bars) or 16 hours (black bars).  
Following dilution, the catalytic activity of NPP7ExFLAG was determined using 
































minutes.  Cobalt treated NPP7ExFLAG had the greatest activityas compared to the 




 at (65 and 79%), respectively.  It is 
interesting to note that the effect of Ca
2+
 improved with additional incubation time to 16 
hours, whereas the effect of Co
2+
 and Ni 
2+
 did not change appreciably, whereas the effect 
of Zn
2+
 decreased significantly. The decrease in activity with prolonged exposure was 
reproducible but our experiments were not adequate to establish why this was the case. 
Further research is is ongoing to investigate the possibility of the divalent metal cations 












5.3.3 Secondary structural analysis by CD spectroscopy 
 Circular dichroism (CD) spectroscopy was employed to study the effect of EDTA 
chelation and divalent metal add back on the global secondary structure of 
NPP7ExFLAG. Wavelength scan data from CD characterization of NPP7ExFLAG 
(untreated control, EDTA treated for 16 hours and EDTA treated with metal ion add back 
for 30 minutes) are shown in Fig. 5.3.  No significant difference was noted in spectra 
 
Fig. 5.2.  Restoration of catalytic activity of NPP7ExFLAG by divalent metals.  
NPP7ExFLAG treated with EDTA for 16 hours was exposed to various divalent metal 
cations and incubated at 4
o
C for either 30 minutes (light grey bars) or 16 hours (dark 
grey bars). The catalytic activity of the EDTA-metal-treated NPP7 was determined 






























obtained between 190-260 nm for any of the sample treatments indicating similar global 




The data obtained from these spectra was deconvoluted using default CDSSTR 
settings on the DicroWeb server accessed at http://dicroweb.cryst.bbk.ac.uk. The percent 
secondary structural compositions calculated for each sample are shown in Table 5.1. For 
 
Fig. 5.3.  Secondary structural effects of EDTA and divalent metals. 









  (full black 
circles) or just EDTA (white circles) before dilution and CD determination. A molar 





































the results to be meaningful, the CDSSTR algorithms have a maximum set error of 0.2. 
The errors shown in Table 5.1 indicate the high confidence in the results obtained using 
this algorithm.  
 














α-helix 31 31 31 32 31 30 
β-sheet 12 11 14 12 13 20 
Random coil 57 57 55 56 55 50 







 5.3.4 Effect of EDTA and divalent metals on thermal stability 
Thermal scans were obtained at 222 nm for the same sample set used to 
characterize global secondary structure.  Data was collected at every degree between 20 
and 100°C and was converted to a measure of the folded/unfolded fraction using the 








) based on the work of  Luthra et. 
al. (6) where [θ]obs is the ellipticity at any temperature, [θ]
den 
is the ellipticity at highest 
temperature, and [θ]
nat
 is the ellipticity at lowest temperature.  Plots of the unfolded 
fraction (1-folded fraction) versus temperature (°C) are shown in Fig. 5.4.  The point at 
which the protein is half unfolded is defined as T50.  Table 5.2 is a compilation of the T50 




C.  EDTA-treated NPP7ExFLAG had the highest T50 value (75°C), 
whereas the zinc-, nickel-, and cobalt-treated samples had T50 values lower than that of 
the untreated sample (60°C, 65°C and 68°C respectively). The T50 of the protein 






Fig.  5.4. Effect of EDTA and divalent metals on the thermal stability of 
NPP7ExFLAG. Thermal denaturation was studied at 222 nm. Samples shown were 
pretreated with EDTA for 16 hours then treated with the divalent metals calcium (white 
squares), cobalt (white circles), nickel (grey circles), zinc (black circles) or CD buffer 

































Table 5.2. Melting temperatures of EDTA/metal-treated NPP7ExFLAG.  
Sample treatment Untreated EDTA Ca2+ Co2+ Ni2+ Zn2+ 




5.4 Discussion  
 A requirement of divalent metal cations for catalytic activity is a general feature 
of all NPP isoforms (1).   Although the specific identity of the metal(s) present in each 
individual NPP isoform has not yet been determined conclusively, several divalent metals 
have previously been shown to restore the activity of NPP2, NPP6 and NPP7 (3, 7, 8).  
Duan et al reported that NPP7 was significantly inhibited by Zn2+ and that the inhibitory 
effect could be prevented by the addition of 2 mM EDTA (1, 5).  It is important to note 
that the experimental conditions under which these previous experiments were performed 
were not detailed in the literature. In the current work we have established that, contrary 
to these earlier reports, NPP7 is inhibited by EDTA at concentrations in the micromolar 
range, although the inhibition takes time.  Since the length of the ETDA treatment was 
not included in the methods described by Duan and coworkers, we cannot be sure if this 
is the root of the differences noted.  We have also established that the catalytic activity of 
this EDTA-treated enzyme is restored by the addition of cobalt, nickel and zinc, 
suggesting that EDTA may have inhibited activity by either abstracting or chelating the 
endogenous divalent metal cations making it unavailable for coordination within the 
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enzyme’s active site.  However our studies were not sufficient to distinguish between 
these possibilities. All metals tested were added in excess at a 1:1 x 10
6
 enzyme to metal 
molar ratio but further work is ongoing where varying concentrations of divalent metal 
cations coupled with dialysis to remove excess metal will be done before studying the 
behavior of the enzyme.  Our results showed that cobalt, nickel and zinc were able to 
restore catalytic function after EDTA treatment.  Despite these results, it remains 
unknown if any of these three candidates is one or more of the divalent, active site metals 
in endogenously expressed NPP7.  Further experimentation using atomic absorption 
spectroscopy is currently ongoing to establish the identity and stoichiometry of the metals 
in the NPP7 active site.  
In exploring the specific role of divalent metals in NPP7ExFLAG function, we 
have established that the secondary structure of the enzyme does not change in the 
presence or absence of the metals in its active site.  Results from our CD experiments 
established that the secondary structural composition of the enzyme remains the same 
regardless of EDTA treatment and metal ion add back (Figure 5.3, Table 5.1).  Since 
catalytic function is effectively abolished with EDTA treatment over 16 hours 
(presumably via endogenous metal removal) we conclude that the divalent metal cations 
play a functional but not a structural role in this enzyme. Our work is not exhaustive in 
the study of metal-binding by NPP7 because our experiments were designed with no 
intermediate metal concentrations used. According to the proposed mechanism, NPP7 
requires two divalent metal cations in the active site for activity and thus should not need 
a large excess of metals for restoration of its activity. Future studies with lower metal 
concentrations in addition to isothermal titration calorimetry experiments may shed light 
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on whether the metals bind at sites other than the known coordination sites and if so are 
there any effects associated with such interactions. 
Interesting data were obtained for the influence of EDTA and divalent metal 
cations on the thermal stability of NPP7ExFLAG.  EDTA treated NPP7ExFLAG, which 
exhibited significantly reduced catalytic activity, had a higher melting temperature than 
the untreated control.  These data suggest that EDTA treatment stabilized the enzyme 
although the secondary structure composition was not altered.  On the other hand, 
addition of the divalent metal cations cobalt, nickel, and zinc (all shown to significant 
restore NPP7 activity following EDTA treatment) led to a decrease in experimentally 
determined T50 of the protein.  Calcium add back restored less activity than cobalt, nickel, 
and zinc but the T50 for this treatment was nearly unchanged from the control.  These 
results suggest that the cations may help provide molecular flexibility required for 
function.  This phenomenon requires further investigation as it is clear from the 
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ACCOMPLISHMENTS AND CONCLUSIONS 
 
 Forty-one years have passed since the first paper was published detailing the 
discovery, by Swedish scientist Ake Nilsson, of the protein that would eventually be 
known as nucleotide pyrophosphatase/ phosphodiesterase (NPP) 7 (1). Duan and 
colleagues purified the enzyme from human bile in 1997 (2). Their characterization 
quickly excluded the enzyme from the sphingomyelinase family due to lack of functional 
and structural similarities with known members including the acid and neutral 
sphingomyelinases. Successive reports in 2002 and 2003 (3, 4) led to the association of 
this Alk-SMase with the nucleotide pyrophosphatase/ phosphodiesterase (NPP) sub-
family of alkaline phosphatase enzymes.  More than thirty years after its discovery, the 
complete cDNA sequence of Alk-SMase was successfully determined (Genbank 
#AY20633) and the enzyme became the most recently identified member of the NPP 
family and it was renamed NPP7 (3).  NPP7 was shown to possess lysolipid 
phosphodiesterase activity similar to the NPP2 and NPP6 isoforms (5) .  NPP7 was 
further classified as a lysophospholipase C (along with NPP6) due to its ability to cleave 
phosphocholine from choline-containing lysolipid phosphodiesters substrates.  To date, 
NPP7 is the only known NPP isoform associated with anticancer effects which are 
proposed to result from the hydrolysis of three endogenous substrates 
lysophosphatidylcholine (LPC), platelet activating factor (PAF), and sphingomyelin (SM) 
(6).  Moreover, NPP7 has been associated with physiological processes such as 
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cholesterol absorption and maturation of the intestinal tract as well as pathological 
processes such as atherosclerosis and inflammatory bowel disease (7).  Despite 
considerable characterization of this enzyme, almost exclusively conducted by Duan and 
coworkers, several unresolved questions remained about the structure and function of 
NPP7.  Our work has attempted to address questions of substrate specificity using novel 
assay methods, with subsequent kinetic analysis.  Questions concerning the role of 
divalent metal cations and substrate specifying determinants were addressed using a 
combination of CD spectroscopy, computational modeling, site-directed mutagenesis and 
kinetic analysis. 
 The work to further characterize known and novel NPP7 substrates started with 
application of a previously described Amplex Red-based assay to the analysis of NPP7 
activity in a multi-well format.  This method allowed for the kinetic characterization of 
NPP7 activity using unmodified known and novel substrates.  Using this approach we 
identified two additional endogenous NPP7 substrates, lyso platelet activating factor 
(lysoPAF) and sphingosylphosphorylcholine (SPC).  In addition, one non-lipid substrate, 
para-nitrophenylphosphocholine (pNPPC) was also identified and used with an adapted 
absorbance assay to further examine NPP7 catalytic function.  These methods are 
important advances for NPP7 as multi-well assays were not described previously.  As 
such, cumbersome and expensive assays (such as radiolabeled substrates with TLC and 
autoradiography) were previously the only choice. 
The study of structure-activity relationships of NPP isoforms has been slowed due 
a lack of physical structural data on NPP7.  The only available crystal structure to use as 
a template at the onset of this work was that of the bacterial Xac NPP (8).  A homology 
112 
model was generated based on this template that was used to analyze enzyme-substrate 
interactions as a guide to site-directed mutagenesis.  Our results identified F275 as an 
essential residue for NPP7 recognition of all choline containing substrates.  These efforts 
are not exhaustive, but highlight further work needed in this area. With regard to 
substrate identification, all the substrates tested here were choline phosphodiesters but a 
survey of other lysophospholipids such as LPI, LPE, and LPG may also help understand 
NPP7 function. In fact, since we found NPP7 to be less discriminating than NPP2 and 
NPP6, it would be worthwhile testing additional analogs such as PE, PI, and PS as well.  
Characterization of additional lipids will be helpful in understanding the role of F275 
since its interaction point in the model complexes was with the choline group of all tested 
substrates.  More work is needed to completely understand substrate specifying 
determinants of NPP7.  The work described herein sets the stage for future experimental 
site-directed mutagenesis of NPP7.  A next logical step would be to examine the role of 
specific sites by mutating them to their complementary residues in other NPP isoforms as 
shown by Table 4.7.  This approach would allow analysis of similarities and differences 
in NPP substrate specificities and regioselectivies. 
 All NPP isoforms are known to be inactivated in the absence of divalent metal 
cations.  However, the identity of these metals remained unknown.  Likewise, it was not 
known whether these metals play only functional, or in addition, structural roles. Using a 
combination of EDTA treatment, metal ion add back, functional analysis and circular 
dichroism, we have established that the divalent metal cations play only functional and 
not structural roles in NPP7.  Experimental data showed that cobalt, nickel and zinc 
restored activity of EDTA-treated NPP7 without significant effects on secondary 
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structure.  Future efforts can be focused on identification of the divalent metals present in 
endogenous NPP7 by atomic absorption spectroscopy and characterization of metals such 
as cobalt in the active site using electron paramagenetic resonance spectroscopy.   
 In conclusion, this work has addressed three significant areas associated with 
human NPP7.  The major legacy of this work has been the methodology generated that 
will allow for future characterization of this important enzyme. 
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Human NPP7 (full length wild type) 
Vectors: pcDNA3.1(+) and pFASTBac1, (upstream: BamH1,  
downstream: Not1) 
 
Amino Acid Sequence 
MRGPAVLLTV ALATLLAPGA GAPVQSQGSQ NKLLLVSFDG FRWNYDQDVD TPNLDAMARD 
GVKARYMTPA FVTMTSPCHF TLVTGKYIEN HGVVHNMYYN TTSKVKLPYH ATLGIQRWWD 
NGSVPIWITA QRQGLRAGSF FYPGGNVTYQ GVAVTRSRKE GIAHNYKNET EWRANIDTVM 
AWFTEEDLDL VTLYFGEPDS TGHRYGPESP ERREMVRQVD RTVGYLRESI ARNHLTDRLN 
LIITSDHGMT TVDKRAGDLV EFHKFPNFTF RDIEFELLDY GPNGMLLPKE GRLEKVYDAL 
KDAHPKLHVY KKEAFPEAFH YANNPRVTPL LMYSDLGYVI HGRINVQFNN GEHGFDNKDM 
DMKTIFRAVG PSFRAGLEVE PFESVHVYEL MCRLLGIVPE ANDGHLATLL PMLHTESALP 





atgagaggcc cggccgtcct cctcactgtg gctctggcca cgctcctggc tcccggggcc 
ggagcaccgg tacaaagtca gggctcccag aacaagctgc tcctggtgtc cttcgacggc 
ttccgctgga actacgacca ggacgtggac acccccaacc tggacgccat ggcccgagac 
ggggtgaagg cacgctacat gacccccgcc tttgtcacca tgaccagccc ctgccacttc 
accctggtca ccggcaaata tatcgagaac cacggggtgg ttcacaacat gtactacaac 
accaccagca aggtgaagct gccctaccac gccacgctgg gcatccagag gtggtgggac 
aacggcagcg tgcccatctg gatcacagcc cagaggcagg gcctgagggc tggctccttc 
ttctacccgg gcgggaacgt cacctaccaa ggggtggctg tgacgcggag ccggaaagaa 
ggcatcgcac acaactacaa aaatgagacg gagtggagag cgaacatcga cacagtgatg 
gcgtggttca cagaggagga cctggatctg gtcacactct acttcgggga gccggactcc 
acgggccaca ggtacggccc cgagtccccg gagaggaggg agatggtgcg gcaggtggac 
cggaccgtgg gctacctccg ggagagcatc gcgcgcaacc acctcacaga ccgcctcaac 
ctgatcatca catccgacca cggcatgacg accgtggaca aacgggctgg cgacctggtt 
gaattccaca agttccccaa cttcaccttc cgggacatcg agtttgagct cctggactac 
ggaccaaacg ggatgctgct ccctaaagaa gggaggctgg agaaggtgta cgatgccctc 
aaggacgccc accccaagct ccacgtctac aagaaggagg cgttccccga ggccttccac 
tacgccaaca accccagggt cacacccctg ctgatgtaca gcgaccttgg ctacgtcatc 
catgggagaa ttaacgtcca gttcaacaat ggggagcacg gctttgacaa caaggacatg 
gacatgaaga ccatcttccg cgctgtgggc cctagcttca gggcgggcct ggaggtggag 
ccctttgaga gcgtccacgt gtacgagctc atgtgccggc tgctgggcat cgtgcccgag 
gccaacgatg ggcacctagc tactctgctg cccatgctgc acacagaatc tgctcttccg 
cctgatggaa ggcctactct cctgcccaag ggaagatctg ctctcccgcc cagcagcagg 
cccctcctcg tgatgggact gctggggacc gtgattcttc tgtctgaggt cgca  
 
Appendix 1.1.   Human NPP7 (full length).  Complete amino acid (top) and verified nucleotide 
(bottom) sequences are shown.  For reference the catalytic (T75) residue is highlighted in black. 






Vectors: pcDNA3.1(+) and pFASTBac1, (upstream: BamH1,  
downstream: Not1) 
 
Amino Acid Sequence 
MRGPAVLLTV ALATLLAPGA GAPVQSQGSQ NKLLLVSFDG FRWNYDQDVD TPNLDAMARD 
GVKARYMTPA FVTMTSPCHF TLVTGKYIEN HGVVHNMYYN TTSKVKLPYH ATLGIQRWWD 
NGSVPIWITA QRQGLRAGSF FYPGGNVTYQ GVAVTRSRKE GIAHNYKNET EWRANIDTVM 
AWFTEEDLDL VTLYFGEPDS TGHRYGPESP ERREMVRQVD RTVGYLRESI ARNHLTDRLN 
LIITSDHGMT TVDKRAGDLV EFHKFPNFTF RDIEFELLDY GPNGMLLPKE GRLEKVYDAL 
KDAHPKLHVY KKEAFPEAFH YANNPRVTPL LMYSDLGYVI HGRINVQFNN GEHGFDNKDM 






atgagaggcc cggccgtcct cctcactgtg gctctggcca cgctcctggc tcccggggcc 
ggagcaccgg tacaaagtca gggctcccag aacaagctgc tcctggtgtc cttcgacggc 
ttccgctgga actacgacca ggacgtggac acccccaacc tggacgccat ggcccgagac 
ggggtgaagg cacgctacat gacccccgcc tttgtcacca tgaccagccc ctgccacttc 
accctggtca ccggcaaata tatcgagaac cacggggtgg ttcacaacat gtactacaac 
accaccagca aggtgaagct gccctaccac gccacgctgg gcatccagag gtggtgggac 
aacggcagcg tgcccatctg gatcacagcc cagaggcagg gcctgagggc tggctccttc 
ttctacccgg gcgggaacgt cacctaccaa ggggtggctg tgacgcggag ccggaaagaa 
ggcatcgcac acaactacaa aaatgagacg gagtggagag cgaacatcga cacagtgatg 
gcgtggttca cagaggagga cctggatctg gtcacactct acttcgggga gccggactcc 
acgggccaca ggtacggccc cgagtccccg gagaggaggg agatggtgcg gcaggtggac 
cggaccgtgg gctacctccg ggagagcatc gcgcgcaacc acctcacaga ccgcctcaac 
ctgatcatca catccgacca cggcatgacg accgtggaca aacgggctgg cgacctggtt 
gaattccaca agttccccaa cttcaccttc cgggacatcg agtttgagct cctggactac 
ggaccaaacg ggatgctgct ccctaaagaa gggaggctgg agaaggtgta cgatgccctc 
aaggacgccc accccaagct ccacgtctac aagaaggagg cgttccccga ggccttccac 
tacgccaaca accccagggt cacacccctg ctgatgtaca gcgaccttgg ctacgtcatc 
catgggagaa ttaacgtcca gttcaacaat ggggagcacg gctttgacaa caaggacatg 
gacatgaaga ccatcttccg cgctgtgggc cctagcttca gggcgggcct ggaggtggag 
ccctttgaga gcgtccacgt gtacgagctc atgtgccggc tgctgggcat cgtgcccgag 
gccaacgatg ggcacctagc tactctgctg cccatgctgc acacagacta caaggacgac 
gatgacaag 
 
Appendix 1.2.  Human NPP7ExFLAG.  Complete amino acid (top) and verified nucleotide 
(bottom) sequences are shown.  For reference the catalytic (T75) residue is highlighted in black 









Human NPP7ExFLAG-F80A  
Vectors: pcDNA3.1(+) and pFASTBac1, (upstream: BamH1,  
downstream: Not1) 
 
Amino acid Sequence 
MRGPAVLLTV ALATLLAPGA GAPVQSQGSQ NKLLLVSFDG FRWNYDQDVD TPNLDAMARD 
GVKARYMTPA FVTMTSPCHA TLVTGKYIEN HGVVHNMYYN TTSKVKLPYH ATLGIQRWWD 
NGSVPIWITA QRQGLRAGSF FYPGGNVTYQ GVAVTRSRKE GIAHNYKNET EWRANIDTVM 
AWFTEEDLDL VTLYFGEPDS TGHRYGPESP ERREMVRQVD RTVGYLRESI ARNHLTDRLN 
LIITSDHGMT TVDKRAGDLV EFHKFPNFTF RDIEFELLDY GPNGMLLPKE GRLEKVYDAL 
KDAHPKLHVY KKEAFPEAFH YANNPRVTPL LMYSDLGYVI HGRINVQFNN GEHGFDNKDM 






atgagaggcc cggccgtcct cctcactgtg gctctggcca cgctcctggc tcccggggcc 
ggagcaccgg tacaaagtca gggctcccag aacaagctgc tcctggtgtc cttcgacggc 
ttccgctgga actacgacca ggacgtggac acccccaacc tggacgccat ggcccgagac 
ggggtgaagg cacgctacat gacccccgcc tttgtcacca tgaccagccc ctgccacgcc 
accctggtca ccggcaaata tatcgagaac cacggggtgg ttcacaacat gtactacaac 
accaccagca aggtgaagct gccctaccac gccacgctgg gcatccagag gtggtgggac 
aacggcagcg tgcccatctg gatcacagcc cagaggcagg gcctgagggc tggctccttc 
ttctacccgg gcgggaacgt cacctaccaa ggggtggctg tgacgcggag ccggaaagaa 
ggcatcgcac acaactacaa aaatgagacg gagtggagag cgaacatcga cacagtgatg 
gcgtggttca cagaggagga cctggatctg gtcacactct acttcgggga gccggactcc 
acgggccaca ggtacggccc cgagtccccg gagaggaggg agatggtgcg gcaggtggac 
cggaccgtgg gctacctccg ggagagcatc gcgcgcaacc acctcacaga ccgcctcaac 
ctgatcatca catccgacca cggcatgacg accgtggaca aacgggctgg cgacctggtt 
gaattccaca agttccccaa cttcaccttc cgggacatcg agtttgagct cctggactac 
ggaccaaacg ggatgctgct ccctaaagaa gggaggctgg agaaggtgta cgatgccctc 
aaggacgccc accccaagct ccacgtctac aagaaggagg cgttccccga ggccttccac 
tacgccaaca accccagggt cacacccctg ctgatgtaca gcgaccttgg ctacgtcatc 
catgggagaa ttaacgtcca gttcaacaat ggggagcacg gctttgacaa caaggacatg 
gacatgaaga ccatcttccg cgctgtgggc cctagcttca gggcgggcct ggaggtggag 
ccctttgaga gcgtccacgt gtacgagctc atgtgccggc tgctgggcat cgtgcccgag 
gccaacgatg ggcacctagc tactctgctg cccatgctgc acacagacta caaggacgac 
gatgacaag 
 
Appendix 1.3.  Human NPP7ExFLAG-F80A.  Complete amino acid (top) and verified 
nucleotide (bottom) sequences are shown.  For reference the catalytic (T75) residue is highlighted 










Vectors: pcDNA3.1(+) and pFASTBac1, (upstream: BamH1,  
downstream: Not1) 
 
Amino acid Sequence 
MRGPAVLLTV ALATLLAPGA GAPVQSQGSQ NKLLLVSFDG FRWNYDQDVD TPNLDAMARD 
GVKARYMTPA FVTMTSPCHF TLVTGKYIEN HGVVHNMYYN TTSKVKFPYH ATLGIQRWWD 
NGSVPIWITA QRQGLRAGSF FYPGGNVTYQ GVAVTRSRKE GIAHNYKNET EWRANIDTVM 
AWFTEEDLDL VTLYFGEPDS TGHRYGPESP ERREMVRQVD RTVGYLRESI ARNHLTDRLN 
LIITSDHGMT TVDKRAGDLV EFHKFPNFTF RDIEFELLDY GPNGMLLPKE GRLEKVYDAL 
KDAHPKLHVY KKEAFPEAFH YANNPRVTPL LMYSDLGYVI HGRINVQFNN GEHGFDNKDM 






atgagaggcc cggccgtcct cctcactgtg gctctggcca cgctcctggc tcccggggcc 
ggagcaccgg tacaaagtca gggctcccag aacaagctgc tcctggtgtc cttcgacggc 
ttccgctgga actacgacca ggacgtggac acccccaacc tggacgccat ggcccgagac 
ggggtgaagg cacgctacat gacccccgcc tttgtcacca tgaccagccc ctgccacttc 
accctggtca ccggcaaata tatcgagaac cacggggtgg ttcacaacat gtactacaac 
accaccagca aggtgaagtt cccctaccac gccacgctgg gcatccagag gtggtgggac 
aacggcagcg tgcccatctg gatcacagcc cagaggcagg gcctgagggc tggctccttc 
ttctacccgg gcgggaacgt cacctaccaa ggggtggctg tgacgcggag ccggaaagaa 
ggcatcgcac acaactacaa aaatgagacg gagtggagag cgaacatcga cacagtgatg 
gcgtggttca cagaggagga cctggatctg gtcacactct acttcgggga gccggactcc 
acgggccaca ggtacggccc cgagtccccg gagaggaggg agatggtgcg gcaggtggac 
cggaccgtgg gctacctccg ggagagcatc gcgcgcaacc acctcacaga ccgcctcaac 
ctgatcatca catccgacca cggcatgacg accgtggaca aacgggctgg cgacctggtt 
gaattccaca agttccccaa cttcaccttc cgggacatcg agtttgagct cctggactac 
ggaccaaacg ggatgctgct ccctaaagaa gggaggctgg agaaggtgta cgatgccctc 
aaggacgccc accccaagct ccacgtctac aagaaggagg cgttccccga ggccttccac 
tacgccaaca accccagggt cacacccctg ctgatgtaca gcgaccttgg ctacgtcatc 
catgggagaa ttaacgtcca gttcaacaat ggggagcacg gctttgacaa caaggacatg 
gacatgaaga ccatcttccg cgctgtgggc cctagcttca gggcgggcct ggaggtggag 
ccctttgaga gcgtccacgt gtacgagctc atgtgccggc tgctgggcat cgtgcccgag 
gccaacgatg ggcacctagc tactctgctg cccatgctgc acacagacta caaggacgac 
gatgacaag 
 
Appendix 1.4.  Human NPP7ExFLAG- L107F.  Complete amino acid (top) and verified 
nucleotide (bottom) sequences are shown.  For reference the catalytic (T75) residue is highlighted 










Vectors: pcDNA3.1(+) and pFASTBac1, (upstream: BamH1,  
downstream: Not1) 
 
Amino acid Sequence 
MRGPAVLLTV ALATLLAPGA GAPVQSQGSQ NKLLLVSFDG FRWNYDQDVD TPNLDAMARD 
GVKARYMTPA FVTMTSPCHF TLVTGKYIEN HGVVHNMYYN TTSKVKLPYH ATLGIQRWWD 
NGSVPIWITA QRQGLRAGSF FAPGGNVTYQ GVAVTRSRKE GIAHNYKNET EWRANIDTVM 
AWFTEEDLDL VTLYFGEPDS TGHRYGPESP ERREMVRQVD RTVGYLRESI ARNHLTDRLN 
LIITSDHGMT TVDKRAGDLV EFHKFPNFTF RDIEFELLDY GPNGMLLPKE GRLEKVYDAL 
KDAHPKLHVY KKEAFPEAFH YANNPRVTPL LMYSDLGYVI HGRINVQFNN GEHGFDNKDM 






atgagaggcc cggccgtcct cctcactgtg gctctggcca cgctcctggc tcccggggcc 
ggagcaccgg tacaaagtca gggctcccag aacaagctgc tcctggtgtc cttcgacggc 
ttccgctgga actacgacca ggacgtggac acccccaacc tggacgccat ggcccgagac 
ggggtgaagg cacgctacat gacccccgcc tttgtcacca tgaccagccc ctgccacttc 
accctggtca ccggcaaata tatcgagaac cacggggtgg ttcacaacat gtactacaac 
accaccagca aggtgaagct gccctaccac gccacgctgg gcatccagag gtggtgggac 
aacggcagcg tgcccatctg gatcacagcc cagaggcagg gcctgagggc tggctccttc 
ttcgccccgg gcgggaacgt cacctaccaa ggggtggctg tgacgcggag ccggaaagaa 
ggcatcgcac acaactacaa aaatgagacg gagtggagag cgaacatcga cacagtgatg 
gcgtggttca cagaggagga cctggatctg gtcacactct acttcgggga gccggactcc 
acgggccaca ggtacggccc cgagtccccg gagaggaggg agatggtgcg gcaggtggac 
cggaccgtgg gctacctccg ggagagcatc gcgcgcaacc acctcacaga ccgcctcaac 
ctgatcatca catccgacca cggcatgacg accgtggaca aacgggctgg cgacctggtt 
gaattccaca agttccccaa cttcaccttc cgggacatcg agtttgagct cctggactac 
ggaccaaacg ggatgctgct ccctaaagaa gggaggctgg agaaggtgta cgatgccctc 
aaggacgccc accccaagct ccacgtctac aagaaggagg cgttccccga ggccttccac 
tacgccaaca accccagggt cacacccctg ctgatgtaca gcgaccttgg ctacgtcatc 
catgggagaa ttaacgtcca gttcaacaat ggggagcacg gctttgacaa caaggacatg 
gacatgaaga ccatcttccg cgctgtgggc cctagcttca gggcgggcct ggaggtggag 
ccctttgaga gcgtccacgt gtacgagctc atgtgccggc tgctgggcat cgtgcccgag 
gccaacgatg ggcacctagc tactctgctg cccatgctgc acacagacta caaggacgac 
gatgacaag 
 
Appendix 1.5.  Human NPP7ExFLAG- Y142A.  Complete amino acid (top) and verified 
nucleotide (bottom) sequences are shown.  For reference the catalytic (T75) residue is highlighted 










Vectors: pcDNA3.1(+) and pFASTBac1, (upstream: BamH1,  
downstream: Not1) 
 
Amino acid Sequence 
MRGPAVLLTV ALATLLAPGA GAPVQSQGSQ NKLLLVSFDG FRWNYDQDVD TPNLDAMARD 
GVKARYMTPA FVTMTSPCHF TLVTGKYIEN HGVVHNMYYN TTSKVKLPYH ATLGIQRWWD 
NGSVPIWITA QRQGLRAGSF FYPGGNVTYQ GVAVTRSRKE GIAHNAKNET EWRANIDTVM 
AWFTEEDLDL VTLYFGEPDS TGHRYGPESP ERREMVRQVD RTVGYLRESI ARNHLTDRLN 
LIITSDHGMT TVDKRAGDLV EFHKFPNFTF RDIEFELLDY GPNGMLLPKE GRLEKVYDAL 
KDAHPKLHVY KKEAFPEAFH YANNPRVTPL LMYSDLGYVI HGRINVQFNN GEHGFDNKDM 






atgagaggcc cggccgtcct cctcactgtg gctctggcca cgctcctggc tcccggggcc 
ggagcaccgg tacaaagtca gggctcccag aacaagctgc tcctggtgtc cttcgacggc 
ttccgctgga actacgacca ggacgtggac acccccaacc tggacgccat ggcccgagac 
ggggtgaagg cacgctacat gacccccgcc tttgtcacca tgaccagccc ctgccacttc 
accctggtca ccggcaaata tatcgagaac cacggggtgg ttcacaacat gtactacaac 
accaccagca aggtgaagct gccctaccac gccacgctgg gcatccagag gtggtgggac 
aacggcagcg tgcccatctg gatcacagcc cagaggcagg gcctgagggc tggctccttc 
ttctacccgg gcgggaacgt cacctaccaa ggggtggctg tgacgcggag ccggaaagaa 
ggcatcgcac acaacgccaa aaatgagacg gagtggagag cgaacatcga cacagtgatg 
gcgtggttca cagaggagga cctggatctg gtcacactct acttcgggga gccggactcc 
acgggccaca ggtacggccc cgagtccccg gagaggaggg agatggtgcg gcaggtggac 
cggaccgtgg gctacctccg ggagagcatc gcgcgcaacc acctcacaga ccgcctcaac 
ctgatcatca catccgacca cggcatgacg accgtggaca aacgggctgg cgacctggtt 
gaattccaca agttccccaa cttcaccttc cgggacatcg agtttgagct cctggactac 
ggaccaaacg ggatgctgct ccctaaagaa gggaggctgg agaaggtgta cgatgccctc 
aaggacgccc accccaagct ccacgtctac aagaaggagg cgttccccga ggccttccac 
tacgccaaca accccagggt cacacccctg ctgatgtaca gcgaccttgg ctacgtcatc 
catgggagaa ttaacgtcca gttcaacaat ggggagcacg gctttgacaa caaggacatg 
gacatgaaga ccatcttccg cgctgtgggc cctagcttca gggcgggcct ggaggtggag 
ccctttgaga gcgtccacgt gtacgagctc atgtgccggc tgctgggcat cgtgcccgag 
gccaacgatg ggcacctagc tactctgctg cccatgctgc acacagacta caaggacgac 
gatgacaag 
 
Appendix 1.6.  Human NPP7ExFLAG- Y166A.  Complete amino acid (top) and verified 
nucleotide (bottom) sequences are shown.  For reference the catalytic (T75) residue is highlighted 










Vectors: pcDNA3.1(+) and pFASTBac1, (upstream: BamH1,  
downstream: Not1) 
 
Amino acid Sequence 
MRGPAVLLTV ALATLLAPGA GAPVQSQGSQ NKLLLVSFDG FRWNYDQDVD TPNLDAMARD 
GVKARYMTPA FVTMTSPCHF TLVTGKYIEN HGVVHNMYYN TTSKVKLPYH ATLGIQRWWD 
NGSVPIWITA QRQGLRAGSF FYPGGNVTYQ GVAVTRSRKE GIAHNYKNAT EWRANIDTVM 
AWFTEEDLDL VTLYFGEPDS TGHRYGPESP ERREMVRQVD RTVGYLRESI ARNHLTDRLN 
LIITSDHGMT TVDKRAGDLV EFHKFPNFTF RDIEFELLDY GPNGMLLPKE GRLEKVYDAL 
KDAHPKLHVY KKEAFPEAFH YANNPRVTPL LMYSDLGYVI HGRINVQFNN GEHGFDNKDM 






atgagaggcc cggccgtcct cctcactgtg gctctggcca cgctcctggc tcccggggcc 
ggagcaccgg tacaaagtca gggctcccag aacaagctgc tcctggtgtc cttcgacggc 
ttccgctgga actacgacca ggacgtggac acccccaacc tggacgccat ggcccgagac 
ggggtgaagg cacgctacat gacccccgcc tttgtcacca tgaccagccc ctgccacttc 
accctggtca ccggcaaata tatcgagaac cacggggtgg ttcacaacat gtactacaac 
accaccagca aggtgaagct gccctaccac gccacgctgg gcatccagag gtggtgggac 
aacggcagcg tgcccatctg gatcacagcc cagaggcagg gcctgagggc tggctccttc 
ttctacccgg gcgggaacgt cacctaccaa ggggtggctg tgacgcggag ccggaaagaa 
ggcatcgcac acaactacaa aaatgcgacg gagtggagag cgaacatcga cacagtgatg 
gcgtggttca cagaggagga cctggatctg gtcacactct acttcgggga gccggactcc 
acgggccaca ggtacggccc cgagtccccg gagaggaggg agatggtgcg gcaggtggac 
cggaccgtgg gctacctccg ggagagcatc gcgcgcaacc acctcacaga ccgcctcaac 
ctgatcatca catccgacca cggcatgacg accgtggaca aacgggctgg cgacctggtt 
gaattccaca agttccccaa cttcaccttc cgggacatcg agtttgagct cctggactac 
ggaccaaacg ggatgctgct ccctaaagaa gggaggctgg agaaggtgta cgatgccctc 
aaggacgccc accccaagct ccacgtctac aagaaggagg cgttccccga ggccttccac 
tacgccaaca accccagggt cacacccctg ctgatgtaca gcgaccttgg ctacgtcatc 
catgggagaa ttaacgtcca gttcaacaat ggggagcacg gctttgacaa caaggacatg 
gacatgaaga ccatcttccg cgctgtgggc cctagcttca gggcgggcct ggaggtggag 
ccctttgaga gcgtccacgt gtacgagctc atgtgccggc tgctgggcat cgtgcccgag 
gccaacgatg ggcacctagc tactctgctg cccatgctgc acacagacta caaggacgac 
gatgacaag 
 
Appendix 1.7.  Human NPP7ExFLAG- E169A.  Complete amino acid (top) and verified 
nucleotide (bottom) sequences are shown.  For reference the catalytic (T75) residue is highlighted 










Vectors: pcDNA3.1(+) and pFASTBac1, (upstream: BamH1,  
downstream: Not1) 
 
Amino acid Sequence 
MRGPAVLLTV ALATLLAPGA GAPVQSQGSQ NKLLLVSFDG FRWNYDQDVD TPNLDAMARD 
GVKARYMTPA FVTMTSPCHF TLVTGKYIEN HGVVHNMYYN TTSKVKLPYH ATLGIQRWWD 
NGSVPIWITA QRQGLRAGSF FYPGGNVTYQ GVAVTRSRKE GIAHNYKNQT EWRANIDTVM 
AWFTEEDLDL VTLYFGEPDS TGHRYGPESP ERREMVRQVD RTVGYLRESI ARNHLTDRLN 
LIITSDHGMT TVDKRAGDLV EFHKFPNFTF RDIEFELLDY GPNGMLLPKE GRLEKVYDAL 
KDAHPKLHVY KKEAFPEAFH YANNPRVTPL LMYSDLGYVI HGRINVQFNN GEHGFDNKDM 






atgagaggcc cggccgtcct cctcactgtg gctctggcca cgctcctggc tcccggggcc 
ggagcaccgg tacaaagtca gggctcccag aacaagctgc tcctggtgtc cttcgacggc 
ttccgctgga actacgacca ggacgtggac acccccaacc tggacgccat ggcccgagac 
ggggtgaagg cacgctacat gacccccgcc tttgtcacca tgaccagccc ctgccacttc 
accctggtca ccggcaaata tatcgagaac cacggggtgg ttcacaacat gtactacaac 
accaccagca aggtgaagct gccctaccac gccacgctgg gcatccagag gtggtgggac 
aacggcagcg tgcccatctg gatcacagcc cagaggcagg gcctgagggc tggctccttc 
ttctacccgg gcgggaacgt cacctaccaa ggggtggctg tgacgcggag ccggaaagaa 
ggcatcgcac acaactacaa aaatcagacg gagtggagag cgaacatcga cacagtgatg 
gcgtggttca cagaggagga cctggatctg gtcacactct acttcgggga gccggactcc 
acgggccaca ggtacggccc cgagtccccg gagaggaggg agatggtgcg gcaggtggac 
cggaccgtgg gctacctccg ggagagcatc gcgcgcaacc acctcacaga ccgcctcaac 
ctgatcatca catccgacca cggcatgacg accgtggaca aacgggctgg cgacctggtt 
gaattccaca agttccccaa cttcaccttc cgggacatcg agtttgagct cctggactac 
ggaccaaacg ggatgctgct ccctaaagaa gggaggctgg agaaggtgta cgatgccctc 
aaggacgccc accccaagct ccacgtctac aagaaggagg cgttccccga ggccttccac 
tacgccaaca accccagggt cacacccctg ctgatgtaca gcgaccttgg ctacgtcatc 
catgggagaa ttaacgtcca gttcaacaat ggggagcacg gctttgacaa caaggacatg 
gacatgaaga ccatcttccg cgctgtgggc cctagcttca gggcgggcct ggaggtggag 
ccctttgaga gcgtccacgt gtacgagctc atgtgccggc tgctgggcat cgtgcccgag 
gccaacgatg ggcacctagc tactctgctg cccatgctgc acacagacta caaggacgac 
gatgacaag 
 
Appendix 1.8.  Human NPP7ExFLAG- E169Q.  Complete amino acid (top) and verified 
nucleotide (bottom) sequences are shown.  For reference the catalytic (T75) residue is highlighted 










Vectors: pcDNA3.1(+) and pFASTBac1, (upstream: BamH1,  
downstream: Not1) 
 
Amino acid Sequence 
MRGPAVLLTV ALATLLAPGA GAPVQSQGSQ NKLLLVSFDG FRWNYDQDVD TPNLDAMARD 
GVKARYMTPA FVTMTSPCHF TLVTGKYIEN HGVVHNMYYN TTSKVKLPYH ATLGIQRWWD 
NGSVPIWITA QRQGLRAGSF FYPGGNVTYQ GVAVTRSRKE GIAHNYKNET EWRANIDTVM 
AWFTEEDLDL VTLYFGEPDS TGHRYGPESP ERREMVRQVD RTVGYLRESI ARNHLTDRLN 
LIITSDHGMT TVDKRAGDLV EFHKFPNFTF RDIEFELLDY GPNGMLLPKE GRLEKVYDAL 
KDAHPKLHVY KKEAFPEAFH YANNPRVTPL LMYSDLGYVI HGRINVQFNN GEHGFDNKDM 






atgagaggcc cggccgtcct cctcactgtg gctctggcca cgctcctggc tcccggggcc 
ggagcaccgg tacaaagtca gggctcccag aacaagctgc tcctggtgtc cttcgacggc 
ttccgctgga actacgacca ggacgtggac acccccaacc tggacgccat ggcccgagac 
ggggtgaagg cacgctacat gacccccgcc tttgtcacca tgaccagccc ctgccacttc 
accctggtca ccggcaaata tatcgagaac cacggggtgg ttcacaacat gtactacaac 
accaccagca aggtgaagct gccctaccac gccacgctgg gcatccagag gtggtgggac 
aacggcagcg tgcccatctg gatcacagcc cagaggcagg gcctgagggc tggctccttc 
ttctacccgg gcgggaacgt cacctaccaa ggggtggctg tgacgcggag ccggaaagaa 
ggcatcgcac acaactacaa aaatgagacg gagtggagag cgaacatcga cacagtgatg 
gcgtggttca cagaggagga cctggatctg gtcacactct acttcgggga gccggactcc 
acgggccaca ggtacggccc cgagtccccg gagaggaggg agatggtgcg gcaggtggac 
cggaccgtgg gctacctccg ggagagcatc gcgcgcaacc acctcacaga ccgcctcaac 
ctgatcatca catccgacca cggcatgacg accgtggaca aacgggctgg cgacctggtt 
gaattccaca agttccccaa cttcaccttc cgggacatcg aggctgagct cctggactac 
ggaccaaacg ggatgctgct ccctaaagaa gggaggctgg agaaggtgta cgatgccctc 
aaggacgccc accccaagct ccacgtctac aagaaggagg cgttccccga ggccttccac 
tacgccaaca accccagggt cacacccctg ctgatgtaca gcgaccttgg ctacgtcatc 
catgggagaa ttaacgtcca gttcaacaat ggggagcacg gctttgacaa caaggacatg 
gacatgaaga ccatcttccg cgctgtgggc cctagcttca gggcgggcct ggaggtggag 
ccctttgaga gcgtccacgt gtacgagctc atgtgccggc tgctgggcat cgtgcccgag 
gccaacgatg ggcacctagc tactctgctg cccatgctgc acacagacta caaggacgac 
gatgacaag 
 
Appendix 1.9.  Human NPP7ExFLAG- F275A.  Complete amino acid (top) and verified 
nucleotide (bottom) sequences are shown.  For reference the catalytic (T75) residue is highlighted 
in black and the FLAG affinity tag is highlighted in grey.  The mutation site is highlighted in 
blue.  
 
 
 
